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ABSTRACT 
 
Gq-coupled GPCRs (Gq-receptors) produce distinct physiological responses despite 
common proximal signaling mechanisms, yet the mechanistic basis for this remains 
unclear. In the heart, Gq-receptors are thought to induce myocyte hypertrophy through a 
mechanism termed excitation-transcription coupling, which provides a mechanistic basis 
for compartmentalization of calcium required for contraction versus inositol-1,4,5-
trisphosphate-dependent intranuclear calcium required for hypertrophy. Here, we identify 
subcellular compartmentalization of Gq-receptor signaling as a mechanistic basis for 
unique Gq-receptor-induced hypertrophic phenotypes in cardiac myocytes. We show 
that a1-adrenergic receptors (a1-ARs) co-localize with phospholipase-Cb1 (PLCb1) and 
phosphatidylinositol-4,5-bisphosphate (PIP2) at the nuclear membrane. Further, nuclear 
a1-ARs induce intranuclear PLCb1 activity leading to the activation of perinuclear and 
cytosolic ERK, histone deacetylase 5 (HDAC5) export, and a robust transcriptional 
response. Conversely, we found that angiotensin receptors localize to the sarcolemma 
and induce sarcolemmal PLCb1 activity leading to the activation of cytosolic ERK, but 
fail to promote HDAC5 nuclear export, while producing a transcriptional response that is 
mostly a subset of a1-induced transcription. In summary, these results link Gq-receptor 
compartmentalization to unique patterns of PLCb1 activation, ERK activation, and 
hypertrophic transcription and significantly revise our understanding of excitation-
transcription coupling. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Cardiac G Protein Coupled Receptors 
G-protein coupled receptors (GPCRs) are the largest family of membrane 
proteins in the human genome and mediate most cellular responses to hormones and 
neurotransmitters (1, 2). GPCRs share common structural morphology which includes 
seven hydrophobic transmembrane domains separated by alternating intracellular and 
extracellular loops with an extracellular amino terminus and an intracellular carboxy 
terminus (2). Vertebrate GPCRs can be divided into 5 families: rhodopsin (701 
receptors), secretin (15 receptors), glutamate (15 receptors), adhesion (24 receptors), 
and Frizzled/Taste (24 receptors) (3). In the heart, receptors from each of the GPCR 
families have been identified. Examples of rhodopsin family members expressed in the 
heart include a1-adrenergic receptors (a1-ARs), b-adrenergic receptors (b-ARs), 
angiotensin receptors (AT-Rs), and endothelin receptors (ET-Rs) (4). Examples of 
secretin family members expressed in the heart include glucagon-like peptide-1 receptor 
(5) and the glucagon receptor (6).  Examples of glutamate family members expressed in 
the heart include the gamma-aminobutyric acid type B receptor 1 and 2 (7). Examples of 
adhesion family members expressed in the heart include ETL (8) and the brain-specific 
angiogenesis inhibitor 1 and 2 receptors (9). Examples of frizzled/taste members 
expressed in the heart include the taste receptor type 1 and taste receptor type 2 (10).   
In order for GPCRs to mediate cellular events secondary to ligand binding, G-
proteins, also known as guanine nucleotide-binding proteins, couple to GPCRs to illicit 
signaling events within the cell. G-proteins fall under two categories: heterotrimeric G-
proteins and small G-proteins belonging to the Ras superfamily. While the Ras 
superfamily of G-proteins is paramount to cellular signaling, this chapter will focus on the 
heterotrimeric G-proteins which consist of the a, b, and g subunits. Currently, there are 
20 known Ga subunits, 6 Gb subunits, and 11 Gg subunits (11). In the basal state, the a, 
b, and g subunits are tightly bound to the GPCR with the a-subunit bound to guanosine 
diphosphate (GDP). Upon ligand binding, the GPCR undergoes a conformational 
change which allows the GPCR to act as a guanine nucleotide exchange factor, 
exchanging the a-subunit GDP for guanosine triphosphate (GTP). The GDP to GTP 
exchange causes the a-subunit to dissociate from the bg subunit and ultimately confer 
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downstream signaling events. The heterotrimeric a-subunits consist of many classes, 
but the five main classes are stimulatory Gas, inhibitory Gai, Gaq, Gaolf, and Ga12/13. 
Canonically, Gas activates adenylyl cyclase, Gai inhibits adenylyl cyclase, Gaq 
activates phospholipase C, Gaolf belongs to the Gas subfamily and thus activates 
adenylyl cyclase, and Ga12/13 regulates the Rho guanine nucleotide exchange factor.  
Examples of receptors that primarily couple to these G protein subunits in cardiac 
myocytes include: 1) Gas coupled b-adrenergic type 1 receptors which increase heart 
rate, cardiac contractility, cardiac action potential conduction velocity, and relaxation 
(12). 2) Gai coupled adenosine receptors which have a negative chronotropic effect by 
suppressing the automaticity of cardiac pacemakers, and a negative dromotropic effect 
through inhibition of AV-nodal conduction (13). 3) Gaq coupled a1-adrenergic receptors 
which mediate positive inotropy, cardiac myocyte cell survival, and physiologic 
hypertrophy (14). 4) Gaolf receptors are only present in the olfactory system. 5) Finally, 
many receptors have been found to couple to multiple G-proteins such as AT-Rs and 
ET-Rs which have also been found to couple to both Gaq and Ga12/13 (15). Yet, 
receptors that uniquely couple to Ga12/13 may have been overlooked due to insufficient 
techniques used to identify G-protein binding (15). Activation of Ga12/13 mediates 
translocation of RhoGEF from the cytosol to the plasma membrane, and stimulate the 
guanine nucleotide exchange factor activity of RhoGEF (15).  
 
1.2 Cardiac Gaq Receptor Signaling 
Of interest to this body of work are the GPCRs that primarily signal through 
Gaq/11 in the heart. These receptors include a1-ARs, ET-Rs, and AT-Rs. Classically, 
when ligand binds the Gaq coupled GPCR (Gq-receptor), GDP is exchanged for GTP 
and the a-subunit dissociates from the bg subunits. The a-subunit activates 
phospholipase Cb (PLCb) at the cell membrane. PLCb cleaves membrane bound 
phosphatidylinositol-4,5-bisphosphate (PIP2) to form diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3). DAG remains associated with the cell membrane and goes on 
to recruit and activate protein kinase C (PKC) family members, ultimately leading to 
phosphorylation of proteins that regulate calcium homeostasis and direct 
phosphorylation of contractile proteins in the heart (16). IP3 is freely diffusible within the 
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cell and goes on to bind its receptor, the inositol trisphosphate receptor (IP3R), to 
release calcium from intracellular stores. Each of these main signaling molecules will be 
discussed in detail below.  
 
 
1.2.1 Phospholipase Cb 
In canonical Gq-receptor signaling, ligand binds to the receptor causing 
dissociation of the G-protein and subsequent activation of PLCb. The PLC isozyme 
family consists of six subfamilies: PLC b, g, d, e, z, and h (17-19). In the heart, the main 
isoforms of PLC expressed are PLCb, g, d, and e (20-22). Cardiac Gq-coupled receptors 
primarily signal through PLCb, and three isoforms of PLCb have been identified in the 
heart: PLCb1, PLCb3, PLCb4 (23). Sensitivity of activation by Gaq is greatest with 
PLCb1 and PLCb3 (24). In the heart, PLCb1 is the major isoform expressed and exists 
as two splice variants PLCb1a and PLCb1b (25). Current literature indicates that 
PLCb1b, but not PLCb1a, localizes to the sarcolemma through interaction of the PLCb1b 
proline rich domain with the scaffolding protein Shank3 (26). Therefore, PLCb1a is 
thought to not be active in cardiac myocytes due to its inability to target the membrane 
and interact with its substrate PIP2 (27). Further, overexpression of the PLCb1b isoform, 
but not the PLCb1a isoform, induced cardiac contractile dysfunction in vivo (27). Yet, 
these results are based on overexpression models and sufficient modalities to study the 
endogenous PLCb1 protein still need to be developed in order to fully understand the 
intricacies of PLCb1 activation in adult cardiac myocytes. New insights on PLCb1 
localization from our lab indicate PLCb1 localizes to the nuclear membrane in adult 
cardiac myocytes (28). While no specific isoform of PLCb1 was identified, this result 
gives evidence to the idea that Gq-receptor signaling through PLCb1 is possible at the 
nucleus in adult cardiac myocytes.  
 
1.2.2 Phosphotidyl-4,5-bisphosphate 
PIP2, the substrate of PLCb1, is generated from the phosphorylation of 
phosphotidylinositol at the 4’ position by phosphotidylinositol 4-kinase and subsequent 
	 4	
phosphorylation at the 5’ position by phosphatidylinositol 4-phosphate 5-kinase (29).  
PIP2 represents less than 1% of total membrane phospholipids, but controls crucial 
signaling cascades in cardiac myocytes (30). Intact PIP2 has been implicated in a variety 
of cell processes including membrane trafficking, membrane-cytoskeletal linkages, ion 
channel gating, and cell signaling (30). Upon Gq-receptor activation, PLCb1 hydrolyzes 
PIP2 into IP3 and DAG, effectively depleting PIP2 at the membrane. Hydrolysis of PIP2 
downstream of Gq-receptor mediated PLCb1 activation can be visualized using the 
pleckstrin homology domain of PLCd fused to GFP (GFP-PHD) (31). The pleckstrin 
homology domain of PLCd selectively binds PIP2 with high affinity at the sarcolemma in 
the basal state in adult cardiac myocytes (32). Our recent work using a nuclear localized 
GFP-PHD and mass spectrometry localize PIP2 to cardiac nuclear membranes which 
supports the idea of nuclear Gq-receptor signaling in cardiac myocytes.  Furthermore, 
due to the low mobility of PIP2 in cardiac membranes, hydrolysis of PIP2 occurs in close 
proximity to the stimulated Gq-receptor indicating a tightly regulated role for PIP2 in Gq-
receptor mediated signal transduction (33).   
 
1.2.3 Diacylglycerol and Protein Kinase C 
One of the products of PLCb1 mediate cleavage of PIP2 is DAG. DAG consists of 
a glycerol molecule linked through ester bonds to two fatty acids at positions one and 
two (34). DAG is a hydrophobic molecule and thus stays bound within the membrane 
complex and does not diffuse throughout the cell. Like PIP2, DAG is not uniformly 
produced throughout the cell upon Gq-receptor stimulation but in discrete pools (34).  
DAG signaling is negatively regulated by diacylglycerol kinases which convert DAG to 
phosphatidic acid. In cardiac myocytes, diacylglycerol kinase a, e, and z are expressed 
with diacylglyercol kinase z being the predominant isoform (35). The main effectors of 
DAG are members of the protein kinase C (PKC) family which interact with DAG at the 
membrane through their conserved C1 domains. Other effectors of DAG include 
chimaerin, protein kinase D, mammalian unc13 (Munc13), Ras guanine-releasing protein 
and myotonic dystrophy kinase-related Cdc42-binding kinase families (36). The PKC 
isozymes that are expressed in cardiac myocytes include the conventional PKCs a and 
b which are activated by DAG and calcium, the novel PKCs d and e which are activated 
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by DAG alone, and the atypical PKCz which is activated by neither DAG nor calcium 
(37). PKC isozymes target a plethora of proteins and thus have influence on many 
signaling cascades in cardiac myocytes. Of note, PKC isozymes modulate cardiac 
contractility through interactions with various cardiac contractile proteins, calcium 
dynamics through interaction with calcium channels, and activation of the p38 mitogen 
activated protein kinase cascade (MAPK) among others (38).   
 
1.2.4 Inositol-1,4,5-trisphosphate  
The other product of PLCb1 mediate cleavage of PIP2 is IP3. Upon Gq-receptor 
stimulation, intracellular IP3 and inositol species in general increases by a factor of >12 
(39). IP3 is freely soluble in the cytosol and goes on to bind to the IP3R in order to 
release calcium from intracellular stores. In the heart, the most abundant IP3R is the 
IP3R2 which localizes to the Z-lines, perinuclear region, and inner nuclear membrane in 
both atrial and ventricular cardiac myocytes (40). Differential roles for the IP3R2 in atrial 
and ventricular myocytes have been suggested, with atrial IP3R2s potentially 
contributing to arrhythmogenesis and ventricular IP3R2s contributing to excitation-
transcription coupling (41-43). In ventricular myocytes, IP3 binding to the IP3R2 at the 
inner nuclear membrane induces a localized calcium release from the nuclear envelope 
(43). Nuclear envelope calcium release activates calcium/calmodulin-dependent protein 
kinase II (CaMKII) and CaMKII phosphorylates histone deacytlase 5 (HDAC5) causing 
HDAC5 nuclear export and derepression of transcription (43). This IP3-calcium-
transcriptional response has been coined excitation-transcription coupling and will be 
discussed in more detail later in this chapter. Apart from the role that calcium acts in 
excitation-transcription coupling, calcium also play a critical role in excitation-contraction 
coupling. During excitation-contraction coupling the depolarization of the cardiac 
sarcolemma causes activation of L-type calcium channels which allows calcium to flow 
into the cardiac myocyte. This influx of calcium triggers calcium induced calcium release 
from the sarcoplasmic reticulum through the ryanodine receptors, ultimately causing 
cardiac myocyte contraction through calcium binding to the troponin-tropomyosin 
complex (44). It is important to note that the calcium mobilized downstream of IP3R2 
stimulation is a separate pool of calcium than that which is mobilized during excitation-
contraction coupling. 
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1.2.5 Mitogen Activated Protein Kinase Cascade 
Another cascade initiated by stimulation of Gq-receptors is the mitogen activated 
protein kinase (MAPK) cascade. The MAPKs consist of p38 kinases, c-Jun N-terminal 
kinases (JNKs), and the functionally redundant extracellular regulated kinases 1 and 2 
(ERK). Gq-receptors, including a1-ARs and ET-Rs, activate all three families of MAPKs 
in cardiac myocytes, with activation of the ERK cascade being the most robust (45-49). 
In adult cardiac myocytes, activation of the JNK downstream of Ras and activation p38 
downstream of PKCs are associated with cellular responses to stress whereas ERK 
activation is generally thought to be associated with hypertrophy and growth (50, 51). 
Activation of Gq-receptors leads to activation of the low molecular weight GTP-binding 
Ras and subsequent translocation and activation of Raf to the membrane. Raf proceeds 
to phosphorylate and activate the MAP3Ks, which in turn phosphorylate and activate the 
MAP2Ks, which then go on to phosphorylate and activate the MAPKs of which ERK is a 
family member. ERK has been implicated in transducing signals of cardiac hypertrophy 
(52-54) through direct phosphorylation of transcription factors such as Elk-1, c-Fos, p53, 
and GATA4 (55). ERK activation has also been linked to increased survival in cardiac 
myocytes exposed to pro-death agonists (56).  
 
1.2.6 Gq-Receptor Desensitization 
While Gq-receptor activation is important to the physiologic function of cardiac 
myocytes, receptor desensitization is just as important. After Gq-receptor cell signaling 
has been initiated, a host of molecules work to attenuate the signaling cascade. The first 
proteins that were identified in the regulation of GPCR signaling were G-protein coupled 
receptor kinases (GRKs) and b-arrestins (57). Generally, GRKs act to desensitize 
GPCRs through phosphorylation of serine and threonine residues within the third 
intracellular loop and carboxyl-terminal tail domains of agonist activated receptors (58). 
In the heart, GRK2, 3 and 5 are expressed with GRKs 2 and 5 being the most abundant 
(58). Further, GRK subtypes 2 and 3 are also able to directly interact with the Gbg 
subunits and PIP2 in order to enhance GPCR phosphorylation and desensitization (59, 
60).  For multiple GPCRs, phosphorylation by GRKs is not sufficient to induce receptor 
desensitization and only upon the recruitment and binding of b-arrestins is the signal 
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attenuated through physical uncoupling of the heterotrimeric G proteins from the 
receptor (58). b-arrestin binding triggers the formation of clathrin-coated pits to traffic the 
receptor for proteasomal degradation or recycling (61). Finally, activation of GTPases 
causes heterotrimeric G proteins to reassemble, and repriming of the receptor for 
stimulation (61). Based upon studies of the a1B-AR subtype, a1-ARs are likely 
phosphorylated and desensitized by GRK2 and/or 3, and can be phosphorylated but not 
desensitized by GRK5 (62). Furthermore, a1B-ARs are readily endocytosed through 
interaction with b-arrestins and clathrin, whereas a1A-ARs are not (63). Based upon 
studies of the ET-R subtype A, ET-R desensitization and internalization likely occurs 
through GRK2 phosphorylation (64). AT-R desensitization occurs through 
phosphorylation by GRK2 and subsequent recruitment and formation of a b-
arrestin/Src/AP-2 complex to promote internalization of the receptor through further 
interaction of ADP-ribosylation factor and clathrin (65, 66). Interestingly, AT-Rs are 
currently the only know Gq-receptor in cardiac myocytes to signal through the b-arrestin 
complex. Activation of AT-Rs using a biased ligand for b-arrestin signaling induces 
vasodilation, no cardiac hypertrophy but still increases cardiac contractility via b-arrestin 
mediated phosphorylation of tropomyosin and other contractile proteins (67).  
 
1.3 Cardiac Nuclear G-Protein Coupled Receptors 
Conventionally, GPCRs were thought to solely localize to the plasma membrane. 
Logically, this paradigm is most rational since activation of the receptors would occur 
through circulating ligand binding to the surface receptor, without further trafficking of the 
ligand to intracellular compartments. While many GPCRs localize to the plasma 
membrane of cells and modulate activity of membrane enzymes, ion channels, and 
second messengers, many GPCRs have also been localized to the nuclear membrane 
in various cell types. These receptors include: AT1R and AT2R; bradykinin B2; a1A-AR 
and a1B-AR; b1, b2, and minimally b3-adrenergic receptors (b1-, b2, b3-AR); endothelin 
subtype A and B receptors (ETRA, ETRB); c-erbB-4; fibroblast growth factor; insulin; 
interferon b; muscarinic cholinergic; nerve growth factor; neuropeptide Y; prostaglandin 
E2; lysophosphatidic acid type 1; urotensin II; and opioid receptors (68). In adult cardiac 
myocytes, functional AT1R, AT2R, ETRB, b1-AR, b3-AR, a1A-AR, and a1B-AR have all 
been localized to the nuclear compartment (56, 69-72). Cardiac nuclear Gaq receptors 
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include a1A-AR, a1B-AR, AT1R, and ETR-B. While there is still much to be defined 
about how each receptor is processed, trafficked, and inserted into the nuclear 
membrane in adult cardiac myocytes, each nuclear Gaq receptor mentioned above has 
a nuclear localization sequence (NLS) that is required to traffic the receptors to the 
nuclear membrane (73).  
Transport of molecules into and out of the nucleus requires passage through 
nuclear pore complexes (NPC). NPCs allow passive diffusion of ions and small proteins 
(<40kDa), but larger molecules must contain the appropriate targeting signal such as an 
NLS or nuclear export signal (NES) (74). The shuttling of macromolecules between the 
cytoplasm and the nucleus is facilitated by carrier proteins that are collectively referred 
to as karyopherins, the largest class of which is the b-karyopherins (75). The first step of 
cytoplasmic to nuclear shuttling is identification of the cargo’s NLS by the b-
karyopherins, importin a and b. The NLS consists of either monopartite or bipartite 
stretches of basic amino acid residues. The monopartite NLS was first described in the 
SV40 large T antigen (PKKKRRV, basic amino acids underlined) (76). The bipartite NLS 
was first described in nucleoplasmin (KRPAATKKAGQAKKKK, basic amino acids 
underlined) (77). Importin a binds the NLS of the cargo protein and facilities binding of 
the cargo protein to importin b forming a complex of importin a and b bound to the cargo 
protein. The cargo is then shuttled to the NPC where importin b facilitates interactions 
with the NPC proteins in order to deliver the cargo protein to the nucleus.  Once 
imported into the nucleus, proteins such as Nup2 and Cse1 act as release factors to 
dissociate importin a and b from the cargo (78). The importins are then shuttled out of 
the nucleus and into the cytoplasm by Cse1, and the process of nuclear transport can 
begin again (74). This NLS mediated nuclear import process is thought to be the way in 
which GPCRs are shuttled from the endoplasmic reticulum and inserted into the nuclear 
membrane (79).  Other mechanisms associated with GPCR nuclear trafficking include 
lateral diffusion through peripheral channels between the NPC and the nuclear 
membrane and movement through the NPC using linkers (80).  
The a1A-AR bipartite NLS (KKAFQNVLRIQCLCRK) and the a1B-AR 
monopartite NLS (RGRGRRRRRRRR) both lie in the carboxy-tail region of their 
respective receptors (81). Mutation of either the a1A-AR or a1B-AR NLS results in 
mislocalization of either receptor, and inability of either receptor to activate downstream 
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signaling in adult cardiac myocytes (81). The AT1R NLS (KKFKKY) was identified in the 
carboxy-tail region of the receptor using mutants in HEK293 cells (82). The ETRB NLS 
has not been identified using rigorous experimental testing, but the NLS mapper (83) 
predicts a bipartite NLS (RFKNCFKSCLCCWCQTFEEKQSLEEKQSCLKF) at the 
carboxy-tail region of the receptor. Further, functional ETRBs have been identified on the 
nuclei of adult ventricular cardiac myocytes (71).  
 
1.4 Cardiac Nuclear Gaq Receptor Signaling 
Activating nuclear receptors requires ligands to either 1) enter the cell from the 
extracellular space through a channel at the cell surface, like a1-ARs or 2) be produced 
within the cell and go on to activate intracellular receptors like AT-Rs and ET-Rs. a1-
ARs are activated by the endogenous cathecholamines epinephrine and norepinephrine. 
In adult cardiac myocytes, catecholamines entry into the cell is facilitated by 
extraneuronal monamine transporter/organic cation transporter 3 (EMT/OCT3) (28). 
OCT3 is present in adult cardiac myocytes and inhibition of OCT3 by corticosterone 
prevents a1-AR activation of downstream signaling partners (28). Further, the latency for 
contractile responses to a1-AR agonism is minutes versus seconds that would be 
expected for a receptor at the cell surface, consistent with translocation of the 
catecholamine from the outside to the inside of the cell (14). Angiotensin II (AngII), the 
ligand for both AT1R and AT2R, can be synthesized in cardiac myocytes (84). AngII is 
formed from the pro-peptides angiotensinogen and angiotensin I. Angiotensinogen is 
cleaved by the protease renin to form the protein angiotensin I. Angiotensin I is cleaved 
by angiotensin converting enzyme (ACE) to form AngII. The basal rate of intracellular 
AngII synthesis in cardiac myocytes is low, but upon stimulation with the b-AR agonist 
isoproterenol or high glucose, intracellular AngII synthesis increases (84). Further, 
cardiac myocytes expressed angiotensinogen, renin, and ACE indicating that the 
machinery is present in order to produce intracellular AngII (84). Endothelin-1 (ET-1) is 
the ligand for both the ETR-A and ETR-B in adult cardiac myocytes (85). ET-1, like 
AngII, is formed from a pro-peptide. Prepro-ET-1 is a 212 amino acid that is formed from 
the transcription of the endothelin gene, Edn1 (86). A 17-aa leader sequence targets 
preproET-1 to the endoplasmic reticulum where it enters the secretory pathway (87). 
Prior to exocytosis, furin-like proteases cleave preproET-1 to a 38-aa protein called big 
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ET-1 (88). The final cleavage step is mediated by endothelin-converting enzymes that 
cleave big ET-1 into active ET-1 (89, 90). Adult cardiac myocytes produce ET-1 at a low 
level in a resting state, but upon electrical stimulation cardiac myocytes increase ET-1 
production at a variable rate (91).  
 
1.4.1. Overview of Nuclear Gq-receptor Signaling Partners 
The Gq-receptor signaling partners Gaq, PLCb1, IP3, and various PKCs have 
been identified in the nucleus of multiple cell types. Gaq has been identified in the 
nuclear membrane of HEK293 cells, primary neural cell cultures, and adult cardiac 
myocytes (92). PLCb1 has been identified in the nucleus of Swiss 3T3 cells (93), rat liver 
cells (94), PC12 pheochromocytoma cells (95), and adult cardiac myocytes (28). IP3 
acting at the inner nuclear membrane through the IP3R2 has been demonstrated to be 
physiologically relevant. In neonatal rat ventricular myocytes, IP3 acting at the nucleus is 
necessary to induce hypertrophy downstream of endothelin 1 (ET-1) acting on the ETRs 
(96). a1-ARs increase calcium spark frequency and induce “calcium waves” in the 
nuclear compartment which do not spread to the cytosol in neonatal rat ventricular 
myocytes (97). In adult cardiac myocytes, activation of the IP3R2 at the inner nuclear 
membrane activates calcium dependent excitation-transcription coupling. Upon IP3 
binding to the IP3R2, calcium is released from the nucleoplasm, the compartment 
separated from the cytoplasm by the nuclear envelope. Experiments on isolated nuclei, 
permeabilized, and intact cardiac myocytes show the activation of the IP3R2 increases 
nuclear calcium (97, 98). This increase in nuclear calcium leads to activation of multiple 
calcium-dependent proteins that modulate gene expression in adult cardiac myocytes 
including calmodulin, CaMKII, protein kinase D (PKD) and calciuneurin.  
 
1.4.2 Calmodulin 
Calmodulin is a highly-conserved calcium binding protein that is ubiquitously 
expressed in mammals, and is considered a major transducer of calcium signals in 
mammalian cells (44). Calmodulin acts as a calcium sensor for other proteins. When 
intracellular calcium concentrations rise, calmodulin binds calcium and undergoes a 
conformational change. This conformational change allows calmodulin to bind effector 
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proteins and thus propagate downstream signaling events (99). The most well studied of 
these calmodulin effector proteins in CaMKII.  
 
1.4.3 Calmodulin Dependent Protein Kinase II 
CaMKII is a serine-threonine kinase that exists as a dodecameric structure (100). 
CaMKII functions to coordinate calcium signals into downstream effects such as 
sarcoplasmic reticulum calcium uptake and release, chronotropic control, excitation-
contraction coupling, and excitation-transcription coupling in adult cardiac myocytes 
(101). CaMKII exists in four isoforms (a, b, g, and d) with the d isoform being the most 
abundant in the heart (102). The two dominant subtypes of CaMKIId expressed in the 
heart are CaMKIIdB and CamKIIdC, and different stoichiometries of these two subtypes 
are what comprise of the final multimeric CaMKIId enzyme (103). CaMKII nuclear 
localization is facilitated through the NLS present on in the CaMKIIdB variable domain 
(104). In the nucleus, activation of CaMKII downsteam of Gq-receptors promotes 
CaMKII mediated phosphorylation of HDAC4 and HDAC5 (105). Phosphorylation of 
HDAC4 and HDAC5 derepresses transcription and promotes re-expression of the fetal 
gene program, a hypertrophic hallmark, including atrial naturetic peptide, brain naturetic 
peptide, myosin light chain-2, and a- and b-myosin heavy chain (106-108).  
 
1.4.4 Protein Kinase D 
PKD belongs to the calcium/calmodulin-dependent protein kinase group of 
serine/threonine kinases. PKD consists of 3 isoforms: PKD1, PKD2, and PKD3 (109, 
110). PKD is a 918-aa serine/threonine kinase that consists of an N-terminal regulatory 
domain,containing 2 cysteine-rich, zinc finger–like motifs and a pleckstrin homology 
domain, and a C-terminal catalytic domain (109, 111). All three PKD isoforms are 
expressed in the neonatal and adult heart with PKD1 being the primary isoform 
expressed (110, 112, 113). Activation of PKD downstream of Gq-receptors, including a1-
ARs, ET-Rs, and AT-Rs, induces 1) phosphorylation of cardiac troponin I at serines 22 
and 23 leading to reduced myofilament calcium sensitivity (114) and 2) phosphorylation 
of HDAC5 through direct interaction which facilitates the binding of 14-3-3 proteins and 
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induces the nuclear export and/or cytosolic retention of HDAC5 in neonatal rat 
ventricular myocytes (115).  
 
1.4.5 Calcineurin 
Calcineurin is a serine/threonine phosphatase, which, like CaMKII, is activated by 
binding of CaM (116). Under basal conditions, calcineurin exists in the cytosol of adult 
cardiac myocytes, but upon sustained, elevated calcium levels or disease states such as 
pressure overload calcineurin undergoes cytosolic to nuclear translocation (117). A 
putitive NLS sequence has been defined from amino acids 171-190 in calcineurin, the 
deletion of which prevents calcineurin cytosolic to nuclear translocation in cardiac 
myocytes (117). In the setting of hypertrophy, activated cytosolic calcineurin 
dephosphorylates the nuclear factor of activated T-cells (NFAT), promoting NFAT and 
calcineurin cytosolic to nuclear translocation (117, 118). Once in the nucleus, calcineurin 
and NFAT act to activate pathologic, but not physiologic, hypertrophic transcriptional 
responses (119, 120). These lines of evidence indicate that all the canonical excitation-
transcription coupling Gq-receptor signaling partners: Gaq, PLCb1, IP3, calmodulin, 
CaMKII, PKD, and calcineurin are present within the nuclei of adult cardiac myocytes.  
 
1.4.5 Regulation and Desensitization of Nuclear Gq-Receptors 
With the discovery of Gq-receptor activation occurring at the nuclei in adult 
cardiac myocytes, much work has been done to identify regulators of nuclear Gq-
signaling. The Gaq coupled GPCR signaling regulators include GRKs and b-Arrestins. 
GRKs are separated into three subfamilies: rhodopsin kinases (GRKs 1 and 7), b-AR 
kinases (GRKs 2 and 3), and the GRK4 subfamily (GRKs 4, 5, and 6). Rhodopsin 
kinases and GRK4 are generally restricted to retina and testes, respectively (121). Only 
GRKs 2, 3, and 5 are appreciably expressed in the human heart, with GRKs 2 and 5 the 
most abundant in the myocardium (122-124). a1-ARs are a preferred substrate of GRK3 
with an IC50 of 7 ± 0.4 pmol/mg of protein (125). ATR endocytosis in HEK293 cells is 
regulated by GRK2/3 (126).  Endothelin receptors are also a preferred substrate of 
GRK3 with an IC50 of 5 ± 0.7 pmol/mg of protein (125). Yet, nuclear localization of 
GRK3 in cardiac myocytes has not been reported and GRK2 has been demonstrated to 
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be excluded from the nuclei in adult cardiac myocytes (127, 128). GRK5, on the other 
hand, includes a nuclear localization sequence and has been demonstrated to act as a 
histone deacetylase kinase (129, 130). Enhanced nuclear GRK5 activity increases 
transcription of genes associated with cardiac hypertrophy, through derepression of 
critical transcription factors (131). In adult rabbit myocytes, stimulation with AngII or 
phenylephrine (PE), an a1-AR agonist, but not ET-1 caused nuclear translocation of 
GRK5 as detected by immunostaining (132). These lines of evidence indicate that GRK5 
may be the GRK regulating a1-AR signaling in intact adult cardiac myocytes due to the 
fact that the discovery of GRK3 regulated a1-AR signaling was done in an artificial 
system (125).  
Canonically, after GRK phosphorylation of the active GPCR, b-Arrestins 
physically uncouple the G-protein from the receptor, terminating signaling which is the 
process known as desensitization (133). The two isoforms of b-arrestin are b-Arrestin 1 
and b-arrestin-2 (134). Along with their role in the physical uncoupling of the G-protein 
from its receptor, b-arrestins have also been shown to promote degradation of second 
messenger molecules via recruitment of phosphodiesterases and kinases (135{Perry, 
2002 #5912, 136). Apart from receptor desensitization, b-Arrestins can also initiate 
signaling cascades. Of note, AT1Rs, specifically the AT1A-R can initiate extracellular 
regulated kinase (ERK) signaling downstream of both Gaq and b-arrestin (137). There is 
currently no evidence to suggest that a1-ARs participate in biased signaling through b-
arrestins. Further, b-arrestin 1 and 2 both contain a nuclear localization sequence in their 
N-domains, and a functional nuclear export signal is only present in the C-domain of b-
arrestin 2 (138). Functionally, nuclear translocation of b-arrestin 1 is able to directly 
induce transcription, which was demonstrated in HEK293 cells transfected with the d-
opoid receptor (139). In neonatal rat myocytes, b-arrestin 2 mediates the nuclear to 
cytoplasmic translocation of HDAC4 downstream of b-adrenergic receptors (140). Taken 
together, both regulators of GPCR signaling, GRKs and b-arrestins, are able to access 
and interact with GPCRs at the cell surface and at the nuclear membrane indicating the 
potential for compartmentalized signaling in adult cardiac myocytes.  
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1.5 Differential Signaling of Cardiac Gaq Receptors 
As stated previously, GPCRs in adult cardiac myocytes are found both on the 
sarcolemma and at the nuclear membrane. For Gq-receptors, functional AT-Rs and ET-
Rs exist at both membranes, and a1-ARs exist primarily at the nuclear membrane (28, 
71{Tadevosyan, 2010 #2920). For AT-Rs and ET-Rs, which localize to both membranes, 
differences in sarcolemmal versus nuclear signaling have been reported (141).  
 In fractionated adult cardiac myocytes, endogenous ATRs are detected by 
Western blot at the plasma and nuclear membranes, with the majority at the plasma 
membrane (69). Sarcolemmal, not nuclear, AT-Rs are thought to induce the detrimental 
effects of AT-Rs in cardiac myocytes since angiotensin receptor blockers improve 
outcomes in heart failure and do not readily to cross the sarcolemma (142). Cardiac 
myocyte cellular responses to sarcolemmal AT-R stimulation include negative inotropy, 
cardiac myocyte cell death, and induction of pathologic hypertrophy (143). Mice lacking 
cardiac AT-Rs are protected from detrimental cardiac remodeling after myocardial 
infarction as compared to their wild type counter parts (144).  Nuclear AT-Rs may also 
lead to the development of cardiac hypertrophy and disease through activation by 
intracellular AngII (145). In neonatal rat ventricular myocytes, expression of adenoviral 
AngII resulted in cellular hypertrophy (146). In mice injected with a cardiac myocyte 
specific AngII plasmid which was retained in the myocytes developed cardiac 
hypertrophy, but transgenic mice whose cardiac myocytes chronically secreted AngII 
failed to develop hypertrophy (146, 147{Baker, 2004 #5941). Taken together, these data 
indicate that both sarcolemmal and nuclear AT-R signaling promotes pathologic cardiac 
myocyte hypertrophy.  
 Radioligand-binding on fractionated adult cardiac myocytes indicates that ETR 
levels are half that of a1-ARs, and identifies 95% of endogenous ETRs at the plasma 
membrane, with 5% of endogenous ETRs in the nuclear fraction (71, 81{Boivin, 2003 
#2613). Sarcolemmal ET-Rs, primarily the A subtype, have been localized to the t-
tubules in adult cardiac myocytes, specifically to the bottom of the t-tubules {Robu, 2003 
#2977}. In cultured adult cardiac myocytes, activation of sarcolemmal ET-Rs by 
endothelin-1 promotes cardiac myocyte cell survival and positive inotropy (85). Yet, 
overexpression of endothelin-1 induces heart failure in mice, whereas ET-R knockout 
mice show less consistent results with global KO inducing embryonic lethality, and 
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cardiac-specific KO suggesting direct and indirect effects to induce heart failure.  (148-
150). Nuclear ET-Rs, primarily the B subtype, regulate nuclear calcium levels 
independent of sarcolemmal ET-Rs and gene expression in adult cardiac myocytes 
through excitation transcription coupling (151). While more work needs to be done to 
further understand the role of nuclear ET-Rs, the current evidence suggests that nuclear 
ET-Rs may be protective whereas sarcolemmal ET-Rs may be detrimental in the heart. 
This conclusion can be based on the evidence that mice that overexpress ET-1 exhibit 
cardiac hypertrophy and heart failure, and that extracellular ET-1 is unlikely to readily 
cross the sarcolemma and activate nuclear ET-Rs.  
 Early work with a1-AR antibodies localized the a1-AR to caveolae in adult 
cardiac myocytes (152), but these antibodies were not validated at the time of 
publication and have since been demonstrated to be non-specific for a1-ARs (153). 
Using validated approaches such as adenoviral expression, binding assays on 
fractionated myocytes, and fluorescently labeled ligands, a1-ARs have primarily been 
localized to the nuclear membrane in adult cardiac myocytes (14). Radioligand-binding 
on fractionated adult cardiac myocytes identifies 80% of endogenous a1-ARs in the 
nuclear fraction (28). Further, signaling through a1-ARs has been localized to the 
nuclear compartment including activation of intranuclear PKC species and initiation of 
ERK activation (28, 154). Taken together, these lines of evidence indicate that nuclear 
Gq-signaling through ET-Rs and a1-ARs may promote cardioprotective signaling 
whereas sarcolemmal and nuclear Gq-signaling through AT-Rs is detrimental.  
 
1.6 Overarching Hypothesis and Aims 
Due to the growing body of evidence that indicates that GPCRs do not solely 
localize to the cell surface in many different cell types including cardiac myocytes (68), 
we are seeking to advance the paradigm that receptor subcellular localization dictates 
the function of the receptor. Specifically, this thesis will focus on the functional 
implication of differential subcellular localization and signaling compartmentalization in 
the context of cardiac myocyte hypertrophic signaling of two Gq-coupled receptors: a1-
ARs and AT-Rs. Convention holds that all Gq-receptors localize to and initiate pathologic 
remodeling from the sarcolemma in cardiac myocytes (155), yet further work with a1-
ARs in adult mouse and human cardiac myocytes indicate that a1-ARs are unique Gq-
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receptors based on function and localization (14). Unlike other Gq-receptors, a1-ARs 
localize to the nucleus and mediate physiologic hypertrophy, positive inotropy, and 
cardiac myocyte cell survival (14). In contrast, AT-Rs behave as prototypical Gq-
receptors and localize to the sarcolemma and mediate pathologic hypertrophy, negative 
inotropy, and cardiac myocyte cell death (143). To test the hypothesis that the 
differential effect of  a1-ARs and AT-Rs on myocyte hypertrophic signaling is based on 
subcellular compartmentalization, we addressed four different aspects of a1-ARs versus 
AT-Rs: 1) localization, 2) immediate proximal signaling through PLCb1, 3) downstream 
signaling through ERK, and 4) terminal signaling through hypertrophic gene activation.  
 
1.6.1 To define and compare the localization of endogenous a1-ARs and 
AT-Rs in adult cardiac myocytes.  
Here we sought to identify the localization of a1-ARs and AT-Rs in intact adult 
cardiac myocytes. While much has been done to localize both a1-ARs and AT-Rs, the 
methods used thus far have been less than ideal. For a1-ARs, previous methods to 
localize the endogenous receptors have included binding assays using fractionated adult 
cardiac myocytes, and treatment with a tagged a1-AR ligand expression (28). Another 
method to determine a1-AR localization has been expression of exogenous a1-ARs 
tagged with a fluorescent moiety in an a1-null background (28). Drawbacks of these 
techniques include: 1) binding assays lack sensitivity, 2) tagged ligand had undesirable 
kinetics and is no longer available, and 3) exogenously expressed, fluorescently tagged 
a1-ARs do not allow for the detection of endogenous receptors. To address these short 
comings, we developed a novel a1-AR ligand that has improved kinetics and has the 
potential to be used in live-cell assays. For AT-Rs, previously used methods to localize 
the receptors have been based on antibody staining in intact adult cardiac myocytes and 
use of fractionated adult cardiac myocytes in Western blotting (69). These antibodies 
have not been validated, and there have been reports that GPCR antibodies overall do 
not detect a specific band (156). To address this short coming, we employed a 
fluorescently tagged Angiotensin II, the ligand for AT-Rs. This is the first time that 
endogenous AT-Rs have been localized in intact adult cardiac myocytes using a 
validated ligand.  
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1.6.2 To define proximal PLCb1 signaling downstream of a1-ARs and AT-Rs  
Here we sought to test the hypothesis that a1-ARs and AT-Rs activate PLCb1 in 
different subcellular compartments corresponding to their localization, with a1-ARs 
activating PLCb1 at the nucleus and AT-Rs activation PLCb1 at the sarcolemma. 
Previous work has indicated that PLCb1 only localizes to and is activated at the 
sarcolemma in adult cardiac myocytes based on the idea that nuclear localized PLCb1 
activity appears most often in undifferentiated cells, and thus is unlikely to occur in adult 
cardiac myocytes which are terminally differentiated (157). The sarcolemmal localization 
and activation of PLCb1 has also been implicated in the development of cardiac 
arrhythmias and pathologic hypertrophy (27). AT-Rs localize to the sarcolemma and so 
we hypothesized that AT-Rs would activate PLCb1 at the sarcolemma, but it was 
unclear if a1-ARs would activate PLCb1 at the sarcolemma since a1-ARs localize to the 
nucleus in adult cardiac myocytes. Thus, we sought to challenge previous knowledge 
and investigate whether PLCb1 and its substrate PIP2 was present at the nucleus and 
whether it was activated downstream of a1-ARs or AT-Rs. In order to study sarcolemmal 
PLCb1 activation downstream of a1-ARs and AT-Rs, we employed a fluorescent PLCb1 
biosensor. Using this biosensor we found that AT-Rs, but not a1-ARs, activate PLCb1 at 
the sarcolemma. In order to study nuclear PLCb1 activation downstream of a1-ARs and 
AT-Rs, we first sought to identify whether or not PLCb1 and PIP2 were present in the 
nuclear membrane of adult cardiac myocytes. Using immunocytochemistry we identified 
PLCb1 at the nuclear envelope, and using a novel mass-spectrometry approach we 
identified PIP2 in the nuclear fraction of adult cardiac myocytes. Further, we used the 
same PLCb1 biosensor and tagged it with a NLS in order to study the activation of 
nuclear PLCb1. We found that a1-ARs, and minimally AT-Rs, activate nuclear PLCb1 in 
adult cardiac myocytes. Thus, our data support the hypothesis that a1-ARs and AT-Rs 
activate proximal signaling through PLCb1 in different subcellular compartments in adult 
cardiac myocytes, with a1-ARs activating PLCb1 primarily at the nucleus and AT-Rs 
activating PLCb1 primarily at the sarcolemma. This is the first report of differential 
PLCb1 localization and activation and PIP2 localization in adult cardiac myocyte nuclear 
membranes.  
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1.6.3 To define Gq-receptor activation of downstream ERK signaling  
Here we sought to test the hypothesis that a1-ARs and AT-Rs differentially 
activate ERK both in degree and intracellular location, and this differential activation 
might explain the differences between a1-ARs and AT-Rs on myocyte survival. In 
cardiac myocytes, convention indicates that Gq-receptor signaling promotes cell death. 
While true for angiotensin receptors (AT-Rs), we previously identified an a1A-adrenergic 
receptor (a1A-AR) ERK survival signaling pathway (56). We previously demonstrated 
that a1-ARs localize to and induce intranuclear signaling in adult cardiac myocytes, 
whereas AT-Rs primarily localize to and signal at the sarcolemma (69, 154). To test this 
hypothesis, we used an ERK activity biosensor to investigate a1-AR and AT-R mediated 
ERK activation with fluorescence lifetime imaging microscopy (FLIM) in adult cardiac 
myocytes. Our results indicate a1-ARs activate ERK more efficaciously with a different 
subcellular localization than AT-Rs, providing mechanistic insight into the differential 
effects on cell survival of these receptors. This is the first report of differential localization 
of ERK activity in adult cardiac myocytes, and it is the first report of FLIM being 
employed to study kinase activation and localization in adult cardiac myocytes. 
 
1.6.4 To define Gq-receptor activation of terminal hypertrophic gene 
activation   
Here, we hypothesized that a1-ARs, due to their close proximity to transcriptional 
machinery at the nucleus, would induce a more robust, cardioprotective transcriptome, 
and that AT-Rs, due to their distance from the nucleus, would induce a more moderate, 
pathologic transcriptome in adult cardiac myocytes. Convention indicates that Gq-
receptors promote pathologic hypertrophy that ultimately leads to heart failure (155). In 
neonatal rat ventricular myocytes, Gq agonists such as AngII and phenylephrine cause 
an increase in cell size, reorganization of sarcomeric proteins, and re-expression of the 
fetal gene program (155). These responses in neonatal rat ventricular myocytes, a 
model of pathologic cardiac hypertrophy, mimic what is observed in animal models that 
over-express Gq (158, 159). While the conclusion of toxic Gq-receptor signaling is based 
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on these models, the models themselves may not represent physiologically relevant 
responses to Gq-stimulation. For example, neonatal rat ventricular myocytes express 
a1-ARs roughly 10-fold more than humans or mouse, which may result in an 
exaggerated hypertrophic response of neonatal rat ventricular myocytes to a1-AR 
stimulation by phenylephrine (14). Further, much of the animal data that implicated Gq-
receptors in pathologic hypertrophic signaling was based on mice that overexpressed 
Gaq 8-fold, which markedly exceeds the 2-fold overexpression of Gaq seen in human 
heart failure (14). Finally, previous work from our lab indicates that a1-ARs activate 
physiologic hypertrophy (160). Physiologic hypertrophy is defined as an increase in heart 
size with either no change or an increase in fuction, this is in direct contrast for 
pathologic hypertrophy which is defined as an increase in heart size with a decrease in 
function. Together, these lines of evidence point to a more dual role for Gq-receptors in 
adult cardiac myocytes with some Gq-receptors such as AT-Rs activating pathologic 
hypertrophy and some Gq-receptors such as a1-ARs activating physiologic hypertrophy. 
Thus, we sought to understand the differences in AT-R and a1-AR mediated 
hypertrophic transcriptional activation in adult mice which express a1-ARs at similar 
levels to humans. To test this hypothesis, we used cardiac myocytes isolated from adult 
mice treated with either the a1-AR agonist phenylephrine or the AT-R agonist AngII and 
RNA-sequencing. We are the first to report differences in Gq-receptor mediated 
activation of transcription at the gene level in the adult mouse heart.  
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2.1 Summary 
Conventional models of GPCR signaling indicate that all GPCRs localize to and 
signal at the plasma membrane. Previous work from multiple groups indicates that this 
convention does not hold in all cell types. In adult cardiac myocytes, Gaq (Gq) coupled 
a1-adrenergic receptors (a1-ARs) localize primarily to the nuclear membrane, whereas 
other Gq receptors have been hypothesized to primarily localize to the sarcolemma. 
Previous modalities to study Gq-receptor localization in adult cardiac myocytes have 
lacked sensitivity and have not been rigorously validated. Here we developed and 
verified a novel tool to study a1-AR nuclear localization and identified a1-ARs primarily 
at the nuclear membrane, consistent with previous reports. Further, we verified a 
commercially available fluorescently labeled ligand to study the localization of 
angiotensin receptors (AT-R) and localized AT-Rs primarily to the sarcolemma in adult 
cardiac myocytes. These results indicate that a1-ARs and AT-Rs localize to different 
compartments in adult cardiac myocytes and that this difference in localization may 
explain the difference in physiologic function of these two Gq-receptors.  
 
2.2 Introduction 
Conventional models of G-protein coupled receptor (GPCR) signaling describe 
ligand binding to plasma membrane GPCRs, which then intitiate downstream signaling 
within the cell. This “outside-in” signaling model suggests that all GPCRs localize to and 
signal at the plasma membrane in all cells. Yet, further work has been done by multiple 
groups using a variety of cell types that indicates that not all GPCRs localize to the 
plasma membrane, and that there are functional GPCRs present on intracellular 
organelles including the nucleus (4, 141). In adult cardiac myocytes, both the a1A- and 
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a1B-AR primarily localize to the nuclear membrane (81). Further, functional studies 
indicate that both a1-AR subtypes are functional at the nuclear membrane and that 
mislocalization of either receptor through mutation of either nuclear localization 
sequence (NLS) prohibits functional signaling (81). Conversely, AT-Rs, specifically the 
type 1 receptor, has been primarily localized to the sarcolemma through studies using 
angiotensin receptor blockers which do not readily cross the sarcolemma and 
unvalidated antibodies (69, 143). Based on these findings, we hypothesized that these 
two Gq-receptors, a1-ARs and AT-Rs, localized to different subcellular compartments in 
adult cardiac myocytes and that this difference in subcellular localization may explain the 
different physiologic outcomes induced by these receptors.  
 
2.3 Methods 
Mouse Lines 
In this study, male and female C57BL/6J mice (10-15 weeks of age) were used as the 
source of primary adult cardiac myocytes. Male and female C57BL/6J mice were 
included due to no historical evidence indicating differences in receptor (a1-AR and AT-
R) density. All animals were treatment naïve and housed under 12-hour light/dark cycle 
and fed standard chow. The use of all animals in this study conformed to the PHS Guide 
for Care and Use of Laboratory Animals and was approved by the University of 
Minnesota Institutional Animal Care and Use Committee. The University of Minnesota 
provides AAALAC-accredited services and resources for using animals in research, 
including animal ordering, care, facilities, housing, and training for researchers and lab 
personnel.  
 
Cell Lines 
The cell line used in this study are HEK293 cells used for adenoviral amplification. 
HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were 
incubated at 5% CO2 and 37°C. No information on sex or cell authentication information 
is available for this cell line.  
 
Isolation and Culture of AMVM  
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As we have described previously (161), adult mouse ventricular myocytes were isolated 
from wild-type male and female C57BL/6J mice between 10 and 15 weeks of age. 
Briefly, mice were anesthetized with isoflurane (3% for induction, 1.5% for maintenance), 
injected with heparin (100 IU/mL), the pleural cavity was opened and the heart removed, 
cannulated on a retrograde perfusion apparatus, and perfused with collagenase type II 
to dissociate ventricular myocytes. Isolated cardiac myocytes were plated at a density of 
50 rod-shaped myocytes per square millimeter on laminin-coated culture dishes. 
Myocytes were cultured in MEM with Hank’s Balanced Salt Solution, 1 mg/ml bovine 
serum albumin, 10 mM 2,3-butanedione monoxime, and 100 U/ml Penicillin in a 2% CO2 
incubator at 37°C. All reagents were purchased from Sigma Aldrich unless otherwise 
specified. Full details of the buffers, enzymes, cell culture medium, all procedures for 
isolation and culturing of AMVM and a detailed diagram of the perfusion apparatus were 
described in detail previously (161). Following plating, myocytes were counted at a 
magnification of 20X to determine cell viability. Adenovirus was added based on 
previously determined multiplicity of infections. Infected myocytes were incubated in a 
2% CO2 incubator at 37°C for 40 hours. If myocytes were left uninfected (a1-AR QDot 
565 and AngII-TAMRA) myocytes were incubated at in a 2% CO2 incubator at 37°C for 
24 hours before beginning experiments.  
 
Isolation of Nuclei from AMVM  
Immediately following isolation, myocytes were allowed to settle by gravity before 
aspiration of supernatant. Myocytes were washed in Buffer A (10 mM K-HEPES, 1.5 mM 
MgCl2, 10 mM KCl, 0.2 mM activated Na3VO4, 1 mM DTT, 50 U/mL DNase, 10 µL/mL 
protease inhibitor cocktail) and centrifuged at 25 x g for 2 minutes. Supernatant was 
aspirated and the myocytes were resuspended in Buffer A. Myocytes were incubated on 
ice for 15 minutes to allow for swelling, and subsequently homogenized for 20 strokes 
using a dounce homogenizer. The homogenate was centrifuged for 2 minutes at 25 x g. 
The supernatant was collected and the pellet was resuspended in Buffer A. The 
homogenization and centrifugation steps were repeated, and the pellet was 
resuspended in Buffer A. The resuspended pellet was then sonicated and the 
homogenate was centrifuged at 2,000 x g for 15 minutes to collect nuclei. 1.95M sucrose 
was added to the pellet and layered on top of 1.95M sucrose in an Ultra-Clear Beckman 
Coulter 14 x 89 mm centrifuge tube. The supernatant containing the myocyte 
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sarcolemmal fraction and cytosolic fractions was added to a separate Ultra-Clear 
Beckman Coulter 14 x 89 mm centrifuge tube. The nuclei (tube 1) and myocyte 
sarcolemmal/cytosolic fractions (tube 2) were centrifuged at 100,000 x g for 90 minutes 
at 4°C. The nuclear pellet from tube 1 was resuspended in Buffer C (20 mM Na-HEPES, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM EGTA, 25% Glycerol, 0.5 mM DTT, 0.5 mM 
PMSF, 10 µL/mL protease inhibitor cocktail). The supernatant from tube 2 was collected 
as the cytosolic fraction and the pellet from the tube 2 was resuspended in Buffer C for 
the myocyte sarcolemmal membrane fraction.  
 
Adenoviral Production 
a1A-GFP: As previously described (56), the a1A-GFP fusion protein was constructed 
with GFP fused to the C-terminus of the human a1A-AR (NM000680) cDNA. The a1A-
AR cDNA was amplified with primers designed to remove the stop codon and insert Bgl 
II and Mlu I restriction sites 5’ and 3’, respectively. The resulting PCR product was 
cloned into pCR2.1-TOPO (Invitrogen), then subcloned into the Bgl II-Mlu I restriction 
sites in the multi-cloning site of the humanized pGFP2-N3 vector with GFP at the C-
terminus. To generate adenovirus, the a1A-GFP was amplified by PCR with primers 
designed to insert Pme I and Xba I restriction sites at the 5’ and 3’ ends, respectively. 
The resulting PCR product was cloned into the pCR2.1-TOPO vector (Invitrogen), then 
subcloned into the Pme I-Xba I restriction sites in the Ad5CMV K-NpA vector under 
control of the CMV promoter.  
Viral amplification and purification: Viral amplification and purification was peformed by 
ViraQuest, Inc. For experiments, culture AMVM were counted at 20X and infected at the 
following multiplicity of infection for a1A-GFP: 1000 (titer: 5.9 x 1010).  
 
Synthesis of a1-QDot-565  
The synthesis of a1-QDot-565 is a two-step process in which the pharmacophore of 
piperazinyl a1AR antagonists is first attached to biotinylated PEG, and the resulting a1-
PEG-biotin product is then joined to a streptavidin coated QDot to create a novel 
fluorescent a1AR antagonist. First, 2-Piperazinyl-4-amino-6,7-dimethoxyquinazoline 
(MW = 289.33) was combined with Poly(ethylene glycol) (N-hydroxysuccinimide 5-
pentanoate) ether 2-(biotinylamino)ethane (average Mn 3,800) at a molecular weight 
ratio of 1:2 in an excess of anhydrous dimethyl sulfoxide in a round bottom flask under a 
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blanket of argon. The mixture was constantly stirred and heated at 40°C for 40 hours. 
The reaction mixture was then added to an excess of HPLC grade diethyl ether, filtered, 
and speed vacuumed overnight. The dried precipitate was resuspended in water and 
subsequently lyophilized for 48 hours. The final product, 2-Piperazinyl-4-amino-6,7-
dimethoxyquinazoline-Poly(ethylene glycol)-biotin, was then stored under a blanket of 
argon at -20°C. Second, 2-Piperazinyl-4-amino-6,7-dimethoxyquinazoline-Poly(ethylene 
glycol)-biotin was resuspended in water and added to streptavidin conjugated QDot 565 
at a ratio of 20:1. The mixture was rocked at 4°C for 30 minutes in a dark tube to make 
the final product, a1-QDot 565.  
 
Localization of a1-ARs in AMVM 
To define the localization of a1-ARs in adult cardiac myocytes, cultured AMVM plated on 
coverslips were incubated with 25 nM a1-QDot 565 for 30 minutes at 37°C in the 
presence and absence of 5 µM prazosin. Myocytes were fixed in 4% paraformaldehyde 
and mounted in Fluoromount G. Confocal images were captured on an Olympus 
FluoView FV1000 IX2 Inverted Confocal Microscope at 60X magnification (oil 
immersion). To detect a1-ARs in the nuclear membrane, myocyte nuclei were isolated, 
and resuspended in buffer N (120.4 mM NaCl, 14.7 mM KCl, 0.6 mM KH2PO4, 0.6 mM 
Na2HPO4, 1.2 mM MgSO4-7H2O, 10 mM Na-HEPES, 4.6 mM NaHCO3, 30 mM Taurine, 
10 mM 2, 3-Butanedione monoxime, 5.5 mM Glucose) (161). Nuclei were subsequently 
incubated with 25 nM a1-QDot 565 for 15 minutes at 37°C. Nuclei were mounted in 
Fluoromount G and imaged with confocal microscopy as above.  
 
Localization of AT-Rs in AMVM 
To define the localization of AT-Rs in adult cardiac myocytes, cultured AMVM plated on 
coverslips were incubated with 1 µM Angiotensin II-TAMRA (AngII-TAMRA) in the 
presence and absence of 5 µM unlabeled AngII for 5 minutes at 37°C. Slides were 
prepared exactly as described for a1-QDot 565. Confocal images were captured on an 
Olympus FluoView FV1000 IX2 Inverted Confocal Microscope at 60X magnification (oil 
immersion). Images were deconvolved for 10 cycles using AutoQuant X3. 3D surface 
plots were created in FIJI using the 3D surface plot plugin. 3D images were created in 
FIJI using the volume viewer plugin.  
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Localization of NCX1 in AMVM 
To define the localization of NCX1 in adult cardiac myocytes, cultured AMVM plated on 
coverslips were fixed and stained with anti NCX1 (1:200 dilution) followed by the 
appropriate AlexaFluor 488 secondary antibody (1:500 dilution). Cells were imaged by 
confocal microscopy.  
 
Statistical Analysis 
All data plotting and statistical analysis was performed using Prism 6 software. All 
information on statistical parameters can be found in figure legends. Images of a1-QDot 
565 (a1-QDot 565, a1-QDot 565 + prazosin, QDot 565 alone (not shown)) were 
quantified using FIJI analyze particle plug-in. Data were analyzed by One-Way ANOVA 
and P<0.05 was considered significant. 
 
2.4 Results 
a1-ARs localize to the nuclei and AT-Rs localize to the sarcolemma in adult 
cardiac myocytes. 
Here, we sought to define the subcellular localization of a1-ARs and AT-Rs in 
adult cardiac myocytes (Figure 2.1). Previously, we demonstrated that endogenous a1-
ARs localize to the nucleus in adult mouse ventricular myocytes (AMVM) ) (28, 81, 154). 
However, reagents typically employed to localize receptors are generally unreliable, 
especially a1-AR subtype-specific antibodies, which lack specificity (153), or fluorescent 
ligands, which are no longer commercially available, but nonetheless had suboptimal 
binding kinetics (28). To overcome these shortcomings, we developed a novel a1-AR 
ligand comprised of 2-piperazinyl-4-amino-6,7-dimethoxyquinazoline, the common 
pharmacophore of a1-AR antagonists such as terazosin and doxazosin, attached to a 
polyethylene glycol linker with a terminal biotin moiety fused to a streptavidin coated 
fluorescent quantum dot (QDot) with an emission wavelength of 565 nm (Figure 2.2A) 
(162). We validated the a1-QDot-565 by infecting wild-type (WT) AMVM with a green 
fluorescent protein labeled a1A-AR (a1A-GFP), incubating infected myocytes with the 
a1-QDot, and co-localizing the GFP and QDot fluorescent signals as an indication of 
receptor binding (Figure 2.2B). In AMVM expressing a1A-GFP, the a1-QDot-565 
fluorescent signal co-localized with the GFP fluorescent signal at the nucleus, and 
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pretreatment with the a1-AR antagonist prazosin diminished QDot fluorescence to nearly 
undetectable levels, demonstrating specificity (Figure 2.2C). We employed the same 
method as above in uninfected WT AMVM, and the a1-QDot-565 bound to endogenous 
a1-ARs at the nuclei in WT AMVM in the absence of prazosin replicating our previous 
findings  (28, 81, 154) (Figures 2.1A and 2.2C, quantified in 2.1B). Further, the a1-
QDot-565 bound endogenous a1-ARs in nuclei isolated from WT AMVM, indicating the 
presence of a1-ARs at the nuclear membrane, again replicating our previous findings 
(28, 81, 154) (Figure 2.1C). Therefore, the a1-QDot-565 fluorescent ligand identified 
endogenous a1-ARs at the nucleus in AMVM, and outperformed prior fluorescent a1-
ligands by improving kinetics (30 minutes) at lower concentrations (25 nM) (28)  
Similar to a1-ARs, the lack of validated antibodies for AT-Rs led us to employ 
another fluorescent ligand to define the localization of endogenous AT-Rs in AMVM. In 
this case, we used angiotensin II (AngII), the endogenous ligand of AT-Rs, labeled with 
the red fluorophore tetramethylrhodamine (TAMRA). We incubated AMVM with AngII-
TAMRA in the absence or presence of unlabeled AngII to demonstrate the specificity of 
AngII-TAMRA (Figures 2.1D, 2.1E and 2.1F). In AMVM, AngII-TAMRA produced a 
distinct localization in confocal sections from the myocyte surface (Figure 2.1E, left 
panel), whereas AngII-TAMRA showed much less specific binding in confocal sections 
from the middle of the myocyte (Figure 2.1D, left panel). Pretreatment with unlabeled 
AngII abolished the AngII-TAMRA signal indicating specificity (Figure 2.1F). To clarify 
receptor localization, slices from the top and middle of the cell were deconvolved, and 
3D surface plots were created that identified AngII-TAMRA signal predominantly at the 
myocyte surface (Figure 2.1D versus 2.1E, center and right panels, arrows indicate 
localization). Finally, a volume rendering was created from a confocal stack of a myocyte 
labeled with AngII-TAMRA demonstrating that the majority of the AngII-TAMRA signal 
localized to the myocyte surface (Figure 2.1G). We attempted to co-stain AngII-TAMRA 
labeled cells with an antibody to the Na/Ca exchanger (NCX) to define sarcolemmal 
localization. However, this was unsuccessful because the antibody staining protocol, 
which included a detergent permeablization step, resulted in loss of AngII-TAMRA 
labeling (163). Alternatively, cardiac myocytes stained with NCX antibody alone show a 
similar staining pattern to AngII-TAMRA (Figure 2.3). Previously, a small population of 
AT-Rs was identified at the nucleus in AMVM based on immunochemical detection and 
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functional assays, although the overall physiologic significance of this population of AT-
Rs is still unclear (69). Further, this population of nuclear AT-Rs, which is activated by 
intracrine AngII, represents only a fraction of total AT-Rs (69). Our results with AngII-
TAMRA indicate that the majority of ligand-accessible AT-Rs exist at the sarcolemma, 
and failure to detect nuclear AT-Rs here is likely due to the fact that neither AngII nor 
AT-R antagonists readily cross the sarcolemma (142). In summary, AngII-TAMRA 
identified endogenous AT-Rs on the sarcolemma, and combined with results from a1-
QDot-565 identification of endogenous a1-ARs at the nucleus, the data indicate that 
endogenous a1-ARs and AT-Rs localize to different subcellular compartments in adult 
cardiac myocytes. 
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Figure 2.1. a1-ARs localize to the nuclei and AT-Rs localize to the sarcolemma in 
adult cardiac myocytes 
	 29	
A. a1-ARs localize to the nuclei in AMVM. a1-QDot-565 was added to cultured WT 
AMVM (25 nM, 30 min, 37°C). Myocytes were fixed and imaged by confocal microscopy 
(60X oil immersion). A representative myocyte is shown, arrows indicate nuclei. Inset is 
intentionally overexposed for visualization of whole cell. Scale bar = 10 µm. B. 
Quantification of a1-QDot-565 localization. The QDot fluorescent intensity from all 
cardiac myocytes was quantified using FIJI (number of cardiac myocytes, n, indicated in 
figure, see also Figure 2.2). QDot-565 alone images not shown. Data are presented as 
mean ± SEM. Data were analyzed by one-way ANOVA, and P<0.05 was considered 
significant. a1-QDot 565 (n=12 myocytes from 4 hearts); a1-QDot 565 + praz (n=3 
myocytes from 2 hearts); QDot 565 alone (n=4 myocytes from 1 heart). Scale bar = 10 
µm. C. a1-QDot-565 labels nuclei isolated from AMVM. Nuclei were isolated from WT 
AMVM and incubated with a1-AR-QDot-565 (25 nM, 15 min, 37°C). Nuclei were fixed 
and imaged as in A. One representative nuclei is shown. D and E.  AT-Rs localize to the 
sarcolemma in AMVM. AngII-TAMRA (1 µM, 5 min, 37°C) was added to WT AMVM. 
Raw optical sections of the middle (top, left) and top (bottom, left) of the myocytes were 
captured by confocal microscopy (60X oil immersion). Deconvolution of optical sections 
from the middle (top, center) and surface (bottom, center) was achieved using 
AutoQuant X3. Arrows indicate AT-R localization at the sarcolemma. 3D surface images 
of deconvolved images middle (top, right) and surface (bottom, right) were created using 
FIJI to demonstrate receptor density. Scale bar = 10 µm. F. AngII-TAMRA is specific for 
AT-Rs in AMVM. WT AMVM were pretreated with an excess of unlabeled AngII (50 µM, 
2 min, 37°C) then incubated with AngII-TAMRA (1 µM, 5 min, 37°C). Signal was 
undetectable indicating specificity. Scale bar = 10 µm. G. Volume plot of AngII-TAMRA 
treated AMVM showing surface localization. 3D volume plot was created using FIJI.  
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Figure 2.2. Synthesis and validation of a1-AR Qdot-565.  
A. Synthesis of a1-AR-QDot-565. The structural backbone of the piperazole class of a1-
AR antagonists, 2-Piperazinyl-4-amino-6,7-dimethoxyquinazoline, was attached to 
biotinylated PEG (Poly(ethylene glycol) (N-hydroxysuccinimide 5-pentanoate) ether 2-
(biotinylamino)ethane). The resulting a1-antagonist-PEG-biotinylated molecule was then 
coupled to streptavidin conjugated QDot-565 to make a1-QDot-565. B. Validation of a1-
QDot-565. To define the specificity of the a1-QDot-565, WT AMVM were infected with 
an adenovirus expressing a1A-GFP and then treated with 25 nM a1AR-QDot-565. Cells 
were fixed and imaged by confocal microscopy. a1A-GFP signal (green), QDot-565 
signal (yellow), and co-localization determined in post-processing (white). Scale bar = 10 
µm.  C. Specificity of a1-QDot-565. Myocytes expressing a1A-GFP were pretreated with 
an excess of unlabeled praz (5 µM) then treated with 25 nM a1-AR-QDot-565. a1A-GFP 
signal (green), QDot-565 signal (yellow) and colocalization determined in post-
processing (white). Scale bar = 10 µm.  D. Specificity of a1-QDot-565 in WT AMVM. To 
demonstrate the specificity of the a1-QDot-565, WT AMVM were pretreated with an 
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excess prazosin (5 µM, 30 min, 37°C) then incubated with a1-AR-QDot-565 (25 nM, 30 
min, 37°C). Two representative myocytes are shown. Scale bar = 10 µm.   
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Figure 2.3. NCX1 localizes to the sarcolemma and not the center of adult cardiac 
myocytes.  
A. Endogenous NCX1 localizes to the sarcolemma in adult cardiac myocytes. WT 
AMVM were isolated, cultured for 24 hours, fixed, permeabilized, and stained with the 
primary antibody against NCX1. Secondary antibody was conjugated to AlexaFluor488. 
Myocytes were imaged by confocal microscopy (60X oil immersion). A representative 
image from the surface and middle of the myocyte are shown. Scale bar = 20 pixels. B. 
3D surface plot of fluorescent intensity of NCX1 signal. 3D Surface images were created 
with FIJI to demonstrate NCX1 fluorescence intensity at the surface and at the middle of 
the cardiac myocyte. 
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2.5 Discussion  
Here we validated a novel tool to study endogenous a1-AR localization and also 
are the first to report AT-R localization using a validated commercially available reagent 
in adult cardiac myocytes. These results are the first step in validating the overarching 
hypothesis of compartmentalization of Gq-receptor signaling in adult cardiac myocytes, 
with nuclear receptors (a1-ARs) being cardioprotective and sarcolemmal receptors (AT-
Rs) being pathologic.  
The concept of GPCR compartmentalization in cardiac myocytes is not without 
precedence. In co-cultures of sympathetic ganglionic neurons and neonatal rat cardiac 
myocytes, b1-ARs localize to regions of axonal contact rich in SAP97, AKAP97, 
catenins, and cadherins, whereas b2-ARs are excluded from these domains (164). In 
adult cardiac myocytes, b1-ARs are distributed over the entire sarcolemma, whereas b2-
ARs are restricted deep within T-tubules (165). Finally, subpopulations of b1-ARs, b3-
ARs, AT1-Rs, and AT2-Rs have been localized to the nuclear membranes in adult 
cardiac myocytes (166). These examples demonstrate that cardiac myocytes express 
GPCRs in different subcellular compartments, and our findings further support this 
model of GPCR expression in adult cardiac myocytes.  
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3.1 Summary 
Upon ligand binding, Gaq-receptors (Gq-receptors) activate phospholipase Cb1 
(PLCb1), which cleaves phosphatidylinositol-4,5-bisphosphate (PIP2) to produce inositol-
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Conventional Gq-receptor signaling 
suggests that all Gq-receptors localize to and initiate this PLCb1 signaling cascade at 
the sarcolemma in adult cardiac myocytes. Further, previous work has indicated that 
both PLCb1 and PIP2 localize solely to the sarcolemma. Yet, based on the finding that 
a1-ARs and AT-Rs localize to different subcellular compartments, we hypothesize that 
a1-ARs and AT-Rs activate proximal signaling in differential subcellular compartments 
as well. Our results indicate that PLCb1 and PIP2 localize to both the sarcolemma and 
nuclear membrane. We also show that a1-ARs and AT-Rs activate PLCb1 in different 
subcellular compartments, with a1-ARs activating PLCb1 at the nuclear membrane and 
AT-Rs activating PLCb1 at the sarcolemma. Taken together, these results demonstrate 
that Gq-receptor mediated activation of signaling is able to occur at both the nuclear 
membrane and sarcolemma in adult cardiac myocytes.  
 
3.2 Introduction 
G-protein coupled receptors that signal through Gaq (Gq-receptors) share a 
common proximal signaling pathway through the activation of phospholipase Cb1 
(PLCb1), which cleaves phosphatidylinositol-4,5-bisphosphate (PIP2) to produce inositol-
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). In adult cardiac myocytes, PLCb1 
and its substrate PIP2 have been localized solely to the sarcolemma where evidence 
suggests that PLCb1 promotes cardiac contractile dysfunction further implicating Gq-
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receptors in promotion of cardiac pathology (27). Yet, our previous results indicate that 
not all Gq-receptors localize to the sarcolemma with a1-ARs primarily localizing to the 
nuclear membrane in adult cardiac myocytes (14). How then do a1-ARs initiate signaling 
if both the enzyme and substrate downstream of Gq-receptor activation reside solely in 
the sarcolemma? Evidence in other cell types suggests that PIP2 localizes to the nuclear 
membrane, but no such studies have been carried out in adult cardiac myocytes (167). 
Thus, we sought to identify the localization of PLCb1 and PIP2 in adult cardiac myocytes 
and to test the hypothesis that that a1-ARs and AT-Rs activate proximal signaling in 
differential subcellular compartments as well. If our experimental evidence supports this 
hypothesis, that would indicate that Gq-receptors can activate distinct subcellular pools 
of PLCb1 further implying that adult cardiac myocytes are capable of compartmentalizing 
Gq-receptor mediated signaling events.  
 
3.3 Methods  
Mouse Lines 
In this study, male and female C57BL/6J mice (10-15 weeks of age) were used as the 
source of primary adult cardiac myocytes. Male and female C57BL/6J mice were 
included due to no historical evidence indicating differences in receptor (a1-AR and AT-
R) density. All animals were treatment naïve and housed under 12-hour light/dark cycle 
and fed standard chow. The use of all animals in this study conformed to the PHS Guide 
for Care and Use of Laboratory Animals and was approved by the University of 
Minnesota Institutional Animal Care and Use Committee. The University of Minnesota 
provides AAALAC-accredited services and resources for using animals in research, 
including animal ordering, care, facilities, housing, and training for researchers and lab 
personnel.  
 
Cell Lines 
Cell lines used in this study include, N38 embryonic mouse hypothalamus cells to 
validate the PLCb1 antibody, and HEK293 cells used for adenoviral amplification. Both 
cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were incubated at 5% 
CO2 and 37°C. No information on sex or cell authentication information is available for 
either cell line.  
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Isolation and Culture of AMVM 
As we have described previously (161), adult mouse ventricular myocytes were isolated 
from wild-type male and female C57BL/6J mice between 10 and 15 weeks of age. 
Briefly, mice were anesthetized with isoflurane (3% for induction, 1.5% for maintenance), 
injected with heparin (100 IU/mL), the pleural cavity was opened and the heart removed, 
cannulated on a retrograde perfusion apparatus, and perfused with collagenase type II 
to dissociate ventricular myocytes. Isolated cardiac myocytes were plated at a density of 
50 rod-shaped myocytes per square millimeter on laminin-coated culture dishes. 
Myocytes were cultured in MEM with Hank’s Balanced Salt Solution, 1 mg/ml bovine 
serum albumin, 10 mM 2,3-butanedione monoxime, and 100 U/ml Penicillin in a 2% CO2 
incubator at 37°C. All reagents were purchased from Sigma Aldrich unless otherwise 
specified. Full details of the buffers, enzymes, cell culture medium, all procedures for 
isolation and culturing of AMVM and a detailed diagram of the perfusion apparatus were 
described in detail previously (161). Following plating, myocytes were counted at a 
magnification of 20X to determine cell viability. Adenovirus was added based on 
previously determined multiplicity of infections. Infected myocytes were incubated in a 
2% CO2 incubator at 37°C for 40 hours. If myocytes were left uninfected (PLCb1 
immunocytochemistry experiments), myocytes were incubated in a 2% CO2 incubator at 
37°C for 24 hours before beginning experiments.  
 
Isolation of Nuclei from AMVM  
Immediately following isolation, myocytes were allowed to settle by gravity before 
aspiration of supernatant. Myocytes were washed in Buffer A (10 mM K-HEPES, 1.5 mM 
MgCl2, 10 mM KCl, 0.2 mM activated Na3VO4, 1 mM DTT, 50 U/mL DNase, 10 µL/mL 
protease inhibitor cocktail) and centrifuged at 25 x g for 2 minutes. Supernatant was 
aspirated and the myocytes were resuspended in Buffer A. Myocytes were incubated on 
ice for 15 minutes to allow for swelling, and subsequently homogenized for 20 strokes 
using a dounce homogenizer. The homogenate was centrifuged for 2 minutes at 25 x g. 
The supernatant was collected and the pellet was resuspended in Buffer A. The 
homogenization and centrifugation steps were repeated, and the pellet was 
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resuspended in Buffer A. The resuspended pellet was then sonicated and the 
homogenate was centrifuged at 2,000 x g for 15 minutes to collect nuclei. 1.95M sucrose 
was added to the pellet and layered on top of 1.95M sucrose in an Ultra-Clear Beckman 
Coulter 14 x 89 mm centrifuge tube. The supernatant containing the myocyte 
sarcolemmal fraction and cytosolic fractions was added to a separate Ultra-Clear 
Beckman Coulter 14 x 89 mm centrifuge tube. The nuclei (tube 1) and myocyte 
sarcolemmal/cytosolic fractions (tube 2) were centrifuged at 100,000 x g for 90 minutes 
at 4°C. The nuclear pellet from tube 1 was resuspended in Buffer C (20 mM Na-HEPES, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM EGTA, 25% Glycerol, 0.5 mM DTT, 0.5 mM 
PMSF, 10 µL/mL protease inhibitor cocktail). The supernatant from tube 2 was collected 
as the cytosolic fraction and the pellet from the tube 2 was resuspended in Buffer C for 
the myocyte sarcolemmal membrane fraction.  
 
Localization of Phospholipase Cb1 in AMVM 
The PLCb1 antibody was validated by measuring PLCb1 mRNA levels and PLCb1 
protein levels by immunocytochemistry following siRNA-mediated knockdown of PLCb1 
in N38 mouse embryonic hypothalamus cells (generous gift from the lab of Dr. 
Alessandro Bartolomucci). N38 cells were plated on glass coverslips at a density of 0.5 x 
106 in 35 mm dishes. 24 hours after plating, cells were transfected with 80 pmol of either 
PLCb1 Gene Solution siRNA or Silencer Negative Control siRNA using Lipofectamine 
RNAiMAX reagent, following manufacturer’s instructions. Cells were incubated at 37°C 
for 72 hours. A portion of cells from each treatment (PLCb1 siRNA and negative control 
siRNA) were harvested for quantitative reverse transcriptase PCR analysis using the 
RNeasy Fibrous Tissue Mini Kit, following manufacturer’s instructions. cDNA was 
synthesized from 2 µg of total RNA using SuperScript III First-Strand Synthesis System 
for RT-PCR. PCR primer sequences are as follows: PLCb1 forward GCC CCT GGA 
GAT TCT GGA GT and PLCb1 reverse GGG AGA CTT GAG GTT CAC CTT T. The 
second portion of cells were fixed and stained with anti PLCb1-C terminal (1:100 
dilution) followed by the appropriate AlexaFluor488 secondary antibody (1:500 dilution). 
Cells were imaged by confocal microscopy. Adult cardiac myocytes were fixed and 
stained using the exact dilution of primary antibody as N38 cells. AF488 (1:500 dilution) 
was used as the secondary antibody.  
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Identification of Nuclear PIP2 
PIP2 extraction was carried out as described by (168) with some modifications. Briefly, 
20 µL of the nuclear fraction was pipetted into 1.7 mL Eppendorf tubes with 225 µL of 
cold methanol added to the samples. After briefly vortexing the samples, 750 µL of cold 
methyl-tert-butyl ether was added to the samples followed by brief vortex and shaking for 
6 minutes at 4°C. 250 µL of HPLC grade water was then added to the samples and 
briefly vortexed and the phases were separated by centrifugation at 14,000 rpm for 2 
minutes. 350 µL of the upper organic phase was collected and placed in 1.5 mL 
Eppendorf tubes and dried in a speed vac. The samples were resuspended with 100 µL 
of methanol/toluene (9:1 v/v), vortexed briefly, and centrifuged at 14,000 rpm for 2 
minutes to remove any debris. 50 µL of the samples was transferred to 250 µL 
autosampler vials. The samples’ electrospray mass spectra were analyzed on a hybrid 
quadrupole triple ion trap mass spectrometer (Triple TOF 5600, AB Sciex Instrument). 
All scans were performed in negative ionization mode and a mass-to-charge (m/z) range 
from 50 to 1200 at an infusion rate of 5 µl/min. PIP2[4’,5’](18:1(9Z)/18:1(9Z)) was 
obtained from Avanti Polar Lipids.  
 
Adenoviral Production 
GFP-PHD and NLS-GFP PHD: The GFP-C1-PLCdelta-PH (GFP-PHD) plasmid was 
obtained from Addgene. To construct NLS-GFP-PHD, the nuclear localization sequence 
(NLS) from the classical monopartite NLS of the SV40 large T-antigen (169) was added 
to the C-terminus of GFP-PHD using mini-gene technology. The sequence of the 
monopartite NLS is: GCA TGT GTC CAA AGA AAA AGC GCA AGG TAA. Integrated 
DNA Technologies synthesized the mini gene that included monopartite NLS flanked by 
an Age I and Xho I restriction sites. pShuttle CMV GFP-PHD was digested with Age I 
and Xho I and the resulting fragment was replaced with the AgeI-monopartite NLS-Xho I 
mini-gene using ligation.  
Viral amplification and purification: All viruses were produced using the AdEasy 
Adenoviral Vector System (Agilent). Briefly, chosen fusion proteins were cloned into the 
pShuttle-CMV vector. Positive clones were recombined into bacterial cell line BJ5183 
using electroporation. DNA was isolated from positive clones and transfected into 
HEK293 cells using Effectene transfection reagent. Virus was amplified for three rounds 
of replication. Viruses were purified using OptiPrep gradients and ultracentrifugation 
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(35,000 x g for 18 hours). Viruses were titered using Adeno-X Rapid Titer Kit per 
manufacturer’s instructions. All constructs were sequence verified in the University of 
Minnesota sequencing core.  For experiments, cultured AMVM were counted at 20X and 
infected with adenoviruses at the following multiplicity of infection: GFP-PHD 100 (titer: 
2.4 x 108) and NLS-GFP-PHD 500 (titer: 1.4 x 1010).  
 
Analysis of Phospholipase Cb1 Activity  
To measure PLCb1 activity in adult cardiac myocytes, cultured AMVM plated on 
coverslips were infected with either 100 MOI GFP-PHD or 500 MOI NLS-GFP-PHD for 
40 hours at 37°C. Myocytes were treated with either vehicle, PE (20 µM) in the absence 
and presence of prazosin (1 mM), or AngII (100 nM) in the absence or presence of 
losartan (5 µM) for 5 minutes at 37°C. Pretreatment with antagonists (prazosin or 
losartan) was carried out for 30 minutes at 37°C before agonist (PE or AngII) treatment. 
Myocytes were fixed and mounted exactly as described for a1-QDot 565. Confocal 
images were captured on an Olympus FluoView FV1000 IX2 Inverted Confocal 
Microscope at 60X magnification (oil immersion). 3D surface plots were created in FIJI 
using the 3D surface plot plugin.  
 
Statistical Analysis 
All data plotting and statistical analysis was performed using Prism 6 software. All 
information on statistical parameters can be found in figure legends. PLCb1 
immunofluorescent intensity was quantified on whole images using FIJI. Data were 
analyzed by student’s t-test and P<0.05 was considered significant. PLCb1 mRNA levels 
were quantified by densitometry using ImageLab (Bio-Rad). Data were analyzed by 
student’s t-test and P<0.05 was considered significant. To quantify activation of PLCb1, 
AMVM expressing GFP-PHD or NLS-GFP-PHD were exposed to agonist or vehicle, and 
classified as responders (movement of probe off the membrane) and non-responders 
(no apparent movement of probe) by another investigator blinded to treatment group. 
Data were analyzed by Chi-Square and P<0.05 was considered significant. 
 
 
 
	 40	
3.4 Results 
Phospholipase Cb1 (PLCb1) and its substrate phosphatidylinositol-4,5-
bisphosphate (PIP2) localize to the nuclei in adult cardiac myocytes.  
Proximal Gq-receptor signaling involves activation of PLCb1 and cleavage of 
PIP2 into IP3 and DAG. While it is generally accepted that Gq-receptors activate PLCb1 
to hydrolyze PIP2 at the sarcolemma (157), it is not clear if this occurs at the nucleus in 
AMVM. Although Gq-receptors localize to the nucleus in AMVM, including a1-ARs 
(Figure 2.1, (28, 81, 154)), as well as small populations of AT-Rs  (69) and ET-Rs (71), 
it is not certain that either PLCb1 or PIP2 localize to the nucleus (32). In other cells, PIP2 
hydrolysis is observed in the nuclear matrix, but is reported to be independent of Gq-
receptor signaling (170). However, nuclear a1-ARs activate intranuclear PKCd in nuclei 
isolated from AMVM  (154), suggesting production of DAG from a yet to be defined 
nuclear phosphatidylinositol species. Further, both AT-Rs and ET-Rs induce intranuclear 
signaling dependent on the production of inositol phosphates in AMVM (69, 171).  
 Based on prior demonstrations of Gq-receptor localization and signaling at the 
nucleus, we sought to clarify whether PLCb1 is localized to the nucleus in adult cardiac 
myocytes. First, we sought to validate potential PLCb1 antibodies. Preferably, we would 
employ AMVM from PLCb1 knockout-mice, but these mice exhibit spontaneous seizures 
and high mortality around 3 weeks of age (172). Alternatively, we attempted to use 
siRNA technology to knock down PLCb1 in AMVM, but were unable to achieve 
significant PLCb1 mRNA knockdown by 40 hours, likely due to low turnover of PLCb1 in 
cultured AMVM. Subsequently, we attempted to validate potential PLCb1 antibodies 
using siRNA technology in the N38 embryonic mouse hypothalamic cell line due to 
PLCb1 enrichment in the brain (REFS). To assess PLCb1 knockdown, N38 cells were 
transfected with either PLCb1 siRNA or scramble siRNA for 72 hours. We observed 
knockdown of PLCb1 mRNA (Figure 3.1C, quantified in Figure 3.1D) and knockdown of 
PLCb protein was visualized by decrease in staining of the PLCb1 antibody (Figure 
3.1A quantified in Figure 3.1B). Finally, we stained wild type AMVM with the PLCb1 
antibody and our results indicate that PLCb1 localizes to the sarcolemma, t-tubules and 
nuclear envelope (Figure 3.2A, nuclei indicated with white arrows).  
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PIP2, the substrate for PLCb1, localizes to the sarcolemma in AMVM (32, 173, 
174). Yet, identifying a population of nuclear PIP2 has been elusive because either 1) 
PIP2 is not present at the nucleus or 2) the methods used to detect PIP2 have been 
insufficient. To address this conundrum, we isolated AMVM nuclei using differential 
centrifugation, and analyzed samples by mass spectrometry to determine if PIP2 is 
present in nuclear membranes in AMVM. To detect the presence of PIP2 species, we ran 
two blanks and two AMVM nuclear samples spiking one of each with commercially 
available 36:2 PIP2, PIP2[4’,5’](18:1(9Z)/18:1(9Z)). Using ESI-MS scan with precursor ion 
m/z 281 (carboxylated anion of oleic acid – C18:1), we were able identify PIP2 36:2 
species in all the samples except the non-spiked blank (Figure 3.2B, left panel). Spectra 
of the peak showing a parent ion m/z 1021 (Figure 3.2B, right panel) confirming the 
identity of the commercially available 36:2 PI(4,5)P2 in the PIP2 spiked blank sample 
with ion fragments at m/z 259, 281, 339, and 419 corresponding to the inositol 
phosphate (IP), the oleic acid backbone, inositol diphosphate (IP2), and inositol 
triphosphate (IP3) components of the fragmented 36:2 PIP2.  
 Similar to previous PIP2 analyses (175), we used negative ion MS/MS to analyze 
the product ions of m/z 1045 (38:4 PIP2), the most abundant PIP2 species in the nuclear 
fraction sample without the PIP2 spike (Figure 3.2C). Ions at m/z 259, 283, 303, 339, 
and 419 correspond to IP, carboxylate anion fatty acyl chains of stearic acid, the 
arachidonic acid backbone, IP2, and IP3, all portions of the fragmented 38:4 PIP2 
spectrum. Our results indicate that PIP2 localizes to membranes within the nuclei of 
AMVM, which to our knowledge is the first such demonstration. In total, our findings 
reveal that PLCb1 and its substrate, PIP2, are found in the same subcellular 
compartments as both the a1-AR (nuclear) and AT-R (sarcolemma), suggesting the 
potential for compartmentalized Gq-receptor signaling in adult cardiac myocytes.  
AT-Rs, but not a1-ARs, activate PLCb1 at the sarcolemma in adult cardiac 
myocytes. 
Based on the observed distinct subcellular compartmentalization of a1-ARs and 
AT-Rs (Figure 2.1), we reasoned that AT-Rs would activate proximal signaling at the 
sarcolemma and a1-ARs at the nuclei. To test this, we measured the 
compartmentalization of Gq-receptor activation of PLCb1 with the PLCb1 activity sensor 
GFP-C1-PLCd-PH (GFP-PHD, Figure 3.3A). GFP-PHD is comprised of GFP fused to 
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the N-terminus of the pleckstrin homology domain of PLCd1, which preferentially binds 
PIP2 over other membrane phosphatidylinositols in vitro (31). In general, GFP-PHD 
associates with PIP2 in membranes in the basal state, and upon Gq-receptor stimulation, 
PLCb1 hydrolyzes PIP2, and as PIP2 is depleted, GFP-PHD dissociates from the 
membrane. In AMVM expressing GFP-PHD, the probe localized to the sarcolemma and 
t-tubules in the basal state, in agreement with previous reports (32). More importantly, 
the a1-agonist phenylephrine (PE), in the absence or presence of prazosin produced no 
change in the localization of GFP-PHD compared to vehicle (Figure 3.3B, quantified in 
3.3C). Conversely, AngII induced a marked dissociation of GFP-PHD from the 
membrane compared to vehicle, which was blocked by the non-selective AT-R 
antagonist losartan indicating a receptor-specific effect (Figure 3.3D, quantified in 3.3E). 
These results demonstrate that AT-Rs, but not a1-ARs, activate PLCb1 at the 
sarcolemma in adult cardiac myocytes consistent with the subcellular 
compartmentalization of each receptor. 
a1-ARs, but not AT-Rs, activate PLCb1 at the nuclear envelope in adult cardiac 
myocytes. 
Interestingly, GFP-PHD was not detected at the nuclear membrane in the basal 
state (Figure 3.3). We suggest there are two explanations for this observation: 1) PIP2 is 
not present in the nuclear membrane, despite our identification of PIP2 in nuclear 
membranes (Figure 3.2) or 2) GFP-PHD, which lacks a NLS, is unable to target the 
nucleus to bind nuclear PIP2. To clarify this and additionally determine if Gq-receptor 
mediated activation of PLCb1 possibly occurs at the nucleus, we inserted a NLS 
sequence at the N-terminus of GFP-PHD to create NLS-GFP-PHD (Figure 3.4A). 
Insertion of a NLS promoted nuclear localization of GFP-PHD (Figure 3.4B and 3.4C) 
suggesting PIP2 is found in the nucleus, in agreement with detection of nuclear PIP2 by 
mass spectrometry (Figure 3.2). Additionally, using the same experimental conditions as 
our experiments with GPF-PHD, the a1-agonist PE induced a marked dissociation of 
NLS-GFP-PHD from the nuclear membrane, which was blocked by prazosin (Figure 
3.4B, quantified in 3.4C). Conversely, AngII, in the absence or presence of losartan, 
produced little change in the localization of NLS-GFP-PHD (Figure 3.4 D, quantified in 
3.4E). These results demonstrate that a1-ARs, but not AT-Rs, primarily activate PLCb1 
at the nuclear membrane in AMVM. The combined results from experiments using GFP-
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PHD and NLS-GFP-PHD indicate that a1-AR- and AT-R-mediated proximal signaling is 
confined to distinct subcellular compartments consistent with receptor localization. 
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Figure 3.1. Validation of PLCb1 antibody in N38 cells. 
A. Visualization of siRNA-mediated PLCb1 protein knockdown. N38 cells (embryonic 
mouse hypothalamic cells) were transfected with either 80 pmol PLCb1 siRNA or 
scrambled siRNA using Lipofectamine RNAiMAX for 72 hours at 37°C. Cells were fixed 
and stained with a primary antibody against PLCb1. Secondary antibody was conjugated 
to AlexaFluor594. Cells were imaged using confocal microscopy (20X). Scale bar = 10 
µm. B. Quantification of siRNA-mediated PLCb1 protein knockdown. Fluorescence 
intensity was measured using FIJI (n=2). Data are represented as mean ± SEM. Data 
were analyzed by paired student’s t-test, and P<0.05 was considered significant. C. 
siRNA-mediated PLCb1 mRNA knockdown. N38 cells were transfected as in A.  After 72 
hours, RNA was harvested using RNAEasy kit, and PLCb1 mRNA levels were measured 
by RT-PCR. Results of densitometry analysis of PLCb1 mRNA levels are shown in D. D. 
Quantification of siRNA-mediated PLCb1 mRNA knockdown.  Ratio of GAPDH to PLCb1 
was quantified using densitometry (n=3). Data are represented as mean ± SEM.  
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Figure 3.2. PLCb1 and PIP2 localize to the nuclear membrane in adult cardiac 
myocytes 
A. Endogenous PLCb1 localizes to the sarcolemma and nuclear membrane in AMVM. 
WT AMVM were isolated, cultured for 24 hours, fixed, permeabilized, and stained with 
the primary antibody against PLCb1. Secondary antibody was conjugated to 
AlexaFluor488. Myocytes were imaged by confocal microscopy (60X oil immersion). 
Arrows indicate nuclear membrane. Two representative images are shown. Scale bar = 
10 µm.  B. Detection and identification of PIP2[4’,5’](18:1(9Z)/18:1(9Z)) in AMVM nuclear 
fractions. Blank and nuclear extracts were analyzed with and without 
PIP2[4’,5’](18:1(9Z)/18:1(9Z)). The yellow peak (not detected) represents blank sample 
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with no PIP2 spike, the green peak represents the blank sample with PIP2 spike, the blue 
peak represents the nuclear fraction with no PIP2 spike and the red peak represents the 
nuclear fraction with PIP2 spike (left panel). ESI-MS scans of the PIP2 spiked blank 
sample with precursor ion m/z 281 showing m/z 1021 identifying the compound as 36:2 
PIP2 (right panel). C. Identification of PIP2 species in AMVM nuclear fractions. Product 
ions of m/z 1045 (38:4 PIP2) of the non-spiked nuclear fraction sample.  
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Figure 3.3. AT-Rs, but not a1-ARS, activate PLCb1 at the sarcolemma in adult 
cardiac myocytes 
A. Schematic representation of GFP-PHD. GFP-PHD consists of the pleckstrin 
homology domain of phospholipase Cd attached to the carboxyl terminus of GFP. The 
PH domain of PLCd has high affinity for PIP2, and in the basal state, GFP-PHD binds to 
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membrane PIP2, and cleavage of PIP2 by PLCb1 releases the probe from the 
membrane, decreasing membrane GFP fluorescence (33). B. GFP-PHD function. In the 
basal state (Basal), GFP-PHD localizes to the sarcolemma bound to PIP2, and upon 
activation of PLCb1 (Activated), PIP2 is cleaved and the probe moves into the cytoplasm. 
C and E. a1-ARs (C) do not activate PLCb1 at the sarcolemma, but AT-Rs do (E). WT 
AMVM expressing GFP-PHD were treated with vehicle (left panels) or PE (20 µM, 5 min, 
37°C) in the absence and presence of prazosin (1 mM, 30 min pretreatment, 37°C, 
middle panels and right panels respectively)), or AngII (100 nM, 5 min, 37°C) in the 
absence and presence of losartan (5 µM, 30 min pretreatment, 37°C, middle and right 
panels respectively). 3D Surface images were created with FIJI to demonstrate GFP-
PHD fluorescence intensity. Scale bar = 10 µm.  D and F. Quantification of sarcolemmal 
PLCb1 activity downstream of a1-ARs (D) and AT-Rs (F). Myocytes were classified by 
another investigator blinded to treatment group as responders defined by GFP-PHD 
movement off the sarcolemma or non-responders defined by no movement of GFP-PHD 
either at baseline or following agonist treatment. Data were analyzed by Chi Square and 
P<0.05 was considered significant. Data are represented as mean ± SEM. Vehicle (n=30 
myocytes from 7 hearts); PE (n=24 myocytes from 4 hearts); AngII (n=29 myocytes from 
4 hearts).  
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Figure 3.4. a1-ARs and, to a lesser extent, AT-Rs activate PLCb1 at the nuclear 
membrane in adult cardiac myocytes.  
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A. Schematic representation of NLS-GFP-PHD. NLS-GFP-PHD consists of GFP-PHD 
tagged with an amino-terminal nuclear localization sequence (NLS) from the SV40 large 
T-antigen to promote localization of the probe to the nucleus. NLS-GFP-PHD is thought 
to operate the same as GFP-PHD (Figure 3.3), but at the nuclear membrane(33). B. 
GFP-PHD function. In the basal state (Basal), GFP-PHD-NLS localizes primarily to the 
nuclear membrane bound to PIP2, and upon activation of PLCb1 (Activated), PIP2 is 
cleaved and the probe moves into the nucleoplasm. C and E. a1-ARs (C) activate 
PLCb1 at the nuclear membrane, but AT-Rs do not (E). WT AMVM expressing NLS- 
GFP-PHD were treated with either vehicle (left panels) or PE (20 µM, 5 min, 37°C) in the 
absence or presence of prazosin (1 mM, 30 min pretreatment, 37°C, middle and right 
panels respectively) or AngII (100 nM, 5 min, 37°C) in the absence and presence of 
losartan (5 µM, 30 min pretreatment, 37°C, middle and right panels respectively).). 
Arrows indicate nuclear membrane activation of PLCb1 by a1-ARs. 3D Surface images 
were created with FIJI to demonstrate NLS-GFP-PHD fluorescence intensity. Scale bar 
= 10 µm. D and F. Quantification of nuclear PLCb1 activity downstream of a1-ARs (D) 
and AT-Rs (F). Myocytes were classified by another investigator blinded to treatment 
group as responders defined by NLS-GFP-PHD movement off the nuclear membrane or 
non-responders defined by no movement of NLS-GFP-PHD either at baseline or 
following agonist treatment. Data were analyzed by Chi Square and P<0.05 was 
considered significant. Data are represented as mean ± SEM. Vehicle (n=30 myocytes 
from 7 hearts); PE (n=14 myocytes from 4 hearts); AngII (n=16 myocytes from 4 hearts). 
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3.5 Discussion  
Here, we identified a potential mechanistic explanation for unique Gq-receptor 
function in adult cardiac myocytes predicated upon subcellular compartmentalization of 
proximal Gq-receptor signaling. We found that both PLCb1 and its substrate PIP2 
localize to the nuclear membrane in adult cardiac myocytes. Further, we found that 
nuclear a1-ARs induce intranuclear activation of PLCb1, whereas sarcolemmal AT-Rs 
induce sarcolemmal activation of PLCb1. This is the first such demonstration of 
differential PLCb1 activation downstream of Gq-receptors in adult cardiac myocytes. 
Previous reports relied upon the GFP-PHD probe as a tool to localize PIP2, but never 
has GFP-PHD or our newly constructed NLS-GFP-PHD probe been used to study the 
activity of PLCb1.  
 The results of this study give further support to the idea that adult cardiac 
myocytes have both the presence of the signaling molecules (Gaq, PIP2, PLCb1) and 
the ability to activate signaling at both the nuclear membrane and the sarcolemma. 
Further, these results support the novel paradigm that not all Gq-signaling is detrimental 
in the setting of heart failure, and that nuclear (a1-AR) signaling is protective whereas 
sarcolemmal (AT-R) signaling is pathologic. Of note, reconstitution of a sarcolemmal 
PLCb1 inhibitory peptide prevents the loss of contractile function in a murine model of 
heart failure (176). This finding indicates that sarcolemmal activation of PLCb1 promotes 
contractile dysfunction which agrees with our model of AT-R sarcolemmal activation of 
PLCb1 inducing contractile dysfunction in adult cardiac myocytes. In addition, activation 
of nuclear PLCb1 downstream of a1-ARs promotes sustained cardiac function and a 
cardioprotective phenotype. These results advance the understanding of 
compartmentalized signaling in adult cardiac myocytes downstream of Gq-receptors.  
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4.1 Summary 
In cardiac myocytes, a1-adrenergic receptors (a1-ARs) promote myocyte 
survival, whereas angiotension receptors (AT-R) promote myocyte death. Because both 
receptors share common proximal Gaq-signaling pathways, we have previously 
suggested that compartmentalization of receptor signaling could contribute to the 
differential phenotype. Here, we used fluorescence lifetime imaging in adult cardiac 
myocytes expressing the ERK activity biosensor EKAR to compare individual myocyte-
specific a1-AR and AT-R mediated activation of ERK. Our results indicate that a1-AR 
signaling induced ERK activity in a higher percentage of myocytes, but the degree of 
activation per myocyte was similar. Furthermore, we found that the localization of ERK 
activity was different, with both receptors activating cytosolic ERK, but only a1-ARs 
activating perinuclear ERK. Further, we found that a1-ARs, but not AT-Rs, promote 
mitochondrial membrane stability. The reduced extent (number of myocytes) and 
differential localization of AT-R mediated ERK activation relative to a1-ARs, and the 
reduction in mitochondrial stability and myocyte survival downstream of AT-Rs relative to 
a1-ARs suggests a possible association with cardiac myocyte survival. 
 
4.2 Introduction 
In cardiac myocytes, convention indicates that Gaq-signaling promotes cell death 
(155). While true for angiotensin receptors (AT-Rs) (177), we previously identified an 
a1A-adrenergic receptor (a1A-AR) ERK survival signaling pathway (56). 
Mechanistically, we have suggested that differential subcellular compartmentalization of 
Gq-coupled receptors could explain this difference (14). We previously demonstrated 
that a1-ARs localize to and induce intranuclear signaling in adult cardiac myocytes (14), 
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whereas AT-Rs primarily localize to and signal at the sarcolemma (69). Therefore, we 
hypothesized that both degree and intracellular location of ERK activation might explain 
the differences between a1-ARs and AT-Rs on myocyte survival. To test this hypothesis, 
we used an ERK activity biosensor to investigate a1-AR and AT-R mediated ERK 
activation with fluorescence lifetime imaging microscopy (FLIM) in adult cardiac 
myocytes. Briefly, our results indicate a1-ARs activate ERK more efficaciously with a 
different subcellular localization than AT-Rs. Further we employed a live-cell 
mitochondrial membrane potential assay using the dye JC-1 which accumulates in intact 
mitochondria. Our results demonstrated that a1-ARs, but not AT-Rs, improve 
mitochondrial membrane potential and cardiac myocyte cell survival. These results 
provide mechanistic insight into the differential effects on cell survival of these receptors.  
 
4.3 Methods  
Adult Mouse Ventricular Myocytes (AMVM) 
AMVM were isolated and cultured as previously described from male and female 10-15 
week old C57BL/6J mice (161).  
 
Extracellular Signal-Regulated Kinase Activity Reporter (EKAR)  
The cytoplasmic EKAR plasmid was a gift from Karel Svoboda (Addgene, #18679). 
EKAR consists of the Cerulean and Venus FRET pair, a substrate phosphorylation 
peptide, and a phospho-binding domain. ERK activation induces phosphorylation of 
EKAR leading to increased FRET (FRET-on) (178) (Figure 4.1C). A cytoplasmic EKAR 
adenovirus was made with the AdEasy System (Agilent). 
 
Fluorescent Lifetime Imaging Microscopy (FLIM) and Analysis of EKAR activity 
Cardiac myocytes were plated on laminin-coated glass coverslips in a 14mm microwell 
within 35mm petri dishes (MatTek), infected with EKAR adenovirus, and cultured for 40 
hours at 37°C.  Myocytes were treated with either 20 µM phenylephrine (PE) or 100 nM 
angiotensin II (AngII) (Sigma Aldrich), at 25°C for 5 minutes. All data was collected on an 
Olympus FluoView FV1000 IX2 Inverted Confocal Microscope with PicoQuant 405 
pulsed laser (80 MHz) at 60X magnification (oil immersion). On average, 1 x 107 photons 
were collected per cell on SPCM software (Becker & Hickl). Data was analyzed using 
FLIMFit software (Imperial College London) using the time-domain fluorescence lifetime 
algorithm for production of intensity images (179). Data was calculated by setting the 
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instrumental response function (IRF) to time zero which was assumed to be the peak of 
the IRF by manipulating the time minimum under the IRF tab (179). Images were fit 
using the following settings: pixel-wise global fitting, global binning, 2-exponential decay 
components, global fitting, and variable projection.  
Due to technical limitations caused by myocyte death from phototoxicity due to 
prolonged laser stimulation during live-cell FLIM and the tendency of contracting 
myocytes to move out of focus, myocyte pairs consisting of untreated (vehicle) and 
treated (PE or AngII) from the same dish were used rather than a single myocyte 
stimulated for 5 minutes. Raw intensities were determined, and were standardized to the 
number of photons collected. Then the level of ERK activation was calculated by the 
fold-change of treated vs. control for paired myocytes from each dish. “Responders” 
were defined as cell pairs which had an intensity ratio of vehicle to drug-treated greater 
than 1 and non-responders were defined as cell pairs which had an intensity ratio of 
vehicle to drug-treated less than or equal to 1. Values are expressed as mean ±SEM. 
Data were analyzed by a paired, two-tailed student’s t-test (treated vs control) and 
presented as fold-change using Prism 6.0 (Graphpad Software, Inc.) and P<0.05 was 
considered significant.  
 
Western Blotting and Analysis 
Cardiac myocytes were plated on 35mm laminin coated dishes, cultured for 24 hours, 
and treated for 5 minutes at 37°C with either PE (20 µM,) or AngII (100 nM), and 
harvested in 2x laemmli sample buffer. Densitometry was performed using Image Lab 
software (Bio-Rad). Data are presented as a ratio of the phosphorylated to total ERK 
signal. Values are expressed as mean ±SEM. Data were analyzed by one-way ANOVA, 
and P<0.05 was considered significant.  
 
JC-1 Mitochondrial Membrane Potential Assay 
Cardiac myocytes were plated on 35mm laminin coated dishes, cultured for 24 hours, 
and treated for 2 hours at 37°C with either Vehicle, Doxorubicin (2 µM), PE (20 µM,) or 
AngII (100 nM). After 2 hours, myocytes were loaded with 5 µM JC-1 (ThermoFisher) for 
30 minutes at 37°C, and after 30 minutes the medium containing JC-1 was aspirated 
and replaced with fresh, dye-free medium. All data was collected on an Olympus 
FluoView FV1000 IX2 Inverted Confocal Microscope using a 10X objective (air) and the 
	 56	
AF594 filter set. 3 images per treatment dish were collected, and fluorescence intensity 
and rod-round count were determined using FIJI.  
 
 
4.4 Results 
Based on the differential effects of a1-ARs and AT-Rs on cardiac myocyte 
survival, we sought to determine if Gq-receptor activation of ERK correlated with cardiac 
myocyte survival. To address this, we treated AMVM with either the a1-AR agonist PE or 
the AT-R agonist AngII and measured ERK phosphorylation at Thr202/Tyr204 as a 
marker of ERK activation. As expected, PE produced a more robust activation of ERK 
than AngII (Figure 4.1A and 4.1B). 
Western blots provide a one-dimensional readout of ERK activation in a 
population of cells or tissue, but provide no insight into degree or localization of cell-
specific kinase activity. To address this, we used FLIM in AMVM expressing the ERK 
activity biosensor EKAR to compare a1-AR and AT-R mediated activation of ERK. PE 
induced ERK activity in 14/21 myocytes (Figure 4.1C, 4.1D, and Figure 4.3). Previously, 
we have demonstrated that the a1A-subtype activates ERK in adult cardiac myocytes 
(56), and therefore, observing PE induced ERK activity in two-thirds of myocytes is 
consistent with prior findings that the a1A-subtype is expressed in only 60% of adult 
cardiac myocytes (180). Importantly, in responding myocytes, PE increased activity by 
17% (Figure 4.1E) and ERK activity was localized to the cytosol and perinuclear space 
(Figure 4.1F). This pattern of a1-induced ERK activity is consistent with our prior 
demonstration that a1-ARs localize to and induce intranuclear signaling in adult cardiac 
myocytes (28, 81, 154). Conversely, AngII induced ERK activity in only 9/22 myocytes 
(Figure 4.2A, 4.2B and Figure 4.3), but in responding myocytes, AngII increased ERK 
activity by 14%, similar in degree to a1-ARs (Figure 4.2C), but only in the cytosol with 
no apparent perinuclear component. 
 In summary, we found that despite sharing common proximal signaling 
pathways, a1-ARs and AT-Rs differentially activate ERK in adult cardiac myocytes. 
Using FLIM, we found that a1-ARs activated ERK in a greater percentage of cardiac 
myocytes than AT-Rs (a1-AR: 14/21; AT-R: 7/22, P<0.05, ChiSquare). While the degree 
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of activation in each responding myocyte was similar (27% vs 20%), we also observed 
that the localization of ERK activity was different, with both receptors activating cytosolic 
ERK, but only a1-ARs activating perinuclear ERK.  
 The anti-apoptotic mechanism of ERK activation in adult cardiac myocytes is 
thought to be due to mitochondrial membrane stabilization (181). Thus, we sought to 
understand the effects of a1-ARs and AT-Rs on mitochondrial membrane potential. To 
address this, we employed JC-1, a dye that is sensitive to mitochondrial membrane 
potential. When the mitochondrial membrane potential is intact, JC-1 accumulates in the 
mitochondria as a multimer and fluoresces in the red spectra. When the mitochondrial 
membrane potential has been lost, JC-1 accumulates in the cytosol as a monomer and 
fluoresces in the green spectra. We treated myocytes with vehicle, doxorubicin which is 
a known pro-apoptotic stimuli (182), PE, or AngII and studied the mitochondrial 
membrane potential using JC-1. Our results indicate that only PE was able to prevent 
the loss of mitochondrial membrane potential and actually improve mitochondrial 
membrane potential in live adult cardiac myocytes (Figure 4.4A and 4.4B). Also, in 
further support of our previous work, a1-ARs, but not AT-Rs, prevented cardiac myocyte 
cell death (Figure 4.4C). In summary, we found that a1-ARs, but not AT-Rs, prevent 
mitochondrial membrane destabilization and promote cardiac myocyte cell survival.  
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Figure 4.1. a1-ARs activate ERK in the cytosol and at the nucleus in two-thirds of 
adult cardiac myocytes.  
A. ERK Western blot. WT AMVM were treated with vehicle, 20 µM PE, or 100 nM AngII 
for 5 min. Western blots were performed with primary antibodies to phosphorylated ERK 
(PERK (Thr202/Tyr204), top) or total ERK (TERK, bottom). B. Quantification of ERK 
phosphorylation. Densitometry presented as a ratio of PERK to TERK signal for n=7 
different cultures. Data were analyzed as described in Methods. C. Schematic of EKAR. 
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D, E. a1-induced EKAR activity. Intensity images are shown (top), with red indicating 
increased EKAR activity, for non-responder (D) and responder myocytes (E) (vehicle, 
left  or 20 µM PE, right). Cerulean fluorescent confocal images are shown for each 
myocyte (bottom). F. Quantification of a1-induced EKAR activity. Fold-change in 
intensity is shown for each group (all myocytes (n=21 from 6 hearts), responders (n=14), 
or non-responders (n=7), calculation described in methods. G. Magnification of nuclei 
from responding myocytes. Arrows indicate nuclei.  
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Figure 4.2. AT-Rs activate ERK in the cytosol in one-third of adult cardiac 
myocytes. 
A,B. AT-R induced EKAR activity. Intensity images are shown (top) for non-responder 
(A) and responder myocytes (B) (vehicle, left  or 100 nM AngII, right). Cerulean 
fluorescent confocal images are shown for each myocyte (bottom). C. Quantification of 
AT-R induced EKAR activity. Fold-change in intensity is shown for each group (all 
myocytes (n=22 from 7 hearts), responders (n=9), or non-responders (n=13), calculation 
described in methods.  
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Figure 4.3. Compilation of ERK1/2 activation downstream of a1-ARs and AT-Rs in 
cardiac myocytes.   
Compilation of all myocytes treated with PE (top) or AngII (bottom) used in Figures 4.1 
and 4.2.  
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Figure 4.4. a1-ARs, but not AT-Rs, promote mitochondrial membrane stabilization 
and cardiac myocyte cell survival. 
A. Mitochondrial membrane potential assay. Images of myocytes treated with vehicle 
(top left), 2 µM doxorubicin (top right), 20 µM PE (bottom left), or 100 nM AngII (bottom 
right) for 2 hours and subsequently loaded with JC-1. Images were collected at 10X 
using confocal microscopy. B. Quantification of mitochondrial membrane potential. 
Fluorescent intensity of cells were determined using FIJI. Raw fluorescent intensity 
counts were plotted using FIJI. One-way ANOVA, P >0.05 was considered significant 
(denoted by *) n=4 hearts. Vehicle=449 cells, Dox=457 cells, AngII=718 cells, PE=682 
cells. C. Quantification of myocyte morphology. Cell counts for number of rod shaped 
and number of round shaped myocyte were carried out using FIJI. n=4 hearts. 
Vehicle=449 cells, Dox=457 cells, AngII=718 cells, PE=682 cells. One-way ANOVA, P 
>0.05 was considered significant (denoted by *)  
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4.5 Discussion  
While a1A-ERK signaling prevents cardiac myocyte death (56), the reduced 
extent (%myocytes) of AT-R mediated ERK activation relative to a1-ARs measured by 
Western blot suggests a possible association between the extent of Gq-coupled receptor 
ERK activation and survival. However, using FLIM, we found that the degree of AT-R 
mediated ERK activation was similar on a per myocyte basis. The mechanistic basis for 
the reduced extent of AT-R mediated ERK activation, and whether failure to activate 
ERK in an individual myocyte contributes to AT-R pro-cell death signaling is unclear. 
Multiple possibilities exist to explain this finding, including that the nuclear a1-AR 
signalosome is more efficacious in activating ERK than the sarcolemmal AT-R 
signalosome, or that analogous to a1-ARs (180), AT-Rs may only be expressed in a 
small number of myocytes. 
In conclusion, using FLIM in adult cardiac myocytes, we identified novel 
differences in a1-AR and AT-R mediated activation of ERK, both degree and 
localization. Also, using JC-1 we found that a1-ARs, but not AT-Rs, promote stability of 
the mitochondrial membrane, and that a1-ARs, but not AT-Rs, promote cardiac myocyte 
cell survival. Taken together, these results provide new insights into ERK mediated 
survival signaling.  
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5.1 Summary 
In adult cardiac myocytes, Gq-receptor mediated excitation-transcription 
coupling, the mechanism whereby myocytes compartmentalize calcium signals to induce 
hypertrophic transcription, has been thought to occur only at the sarcolemma. Yet, 
based on differential Gq-receptor localization and activation of proximal signaling 
pathways, we sought to test the hypothesis that nuclear a1-ARs will promote will 
promote a unique transcriptional response versus AT-Rs based on their differential 
localization. We hypothesized that this transcriptional response would mirror the 
physiologic response downstream of both receptors. Our results indicate that a1-ARs, 
but not AT-Rs, induce IP3 sensitive HDAC5 export and that a1-ARs more robustly 
activate transcription in adult cardiac myocytes with AT-R induced transcriptional 
responses largely being a subset of a1-ARs’. These results identify distinct difference in 
the transcriptomes induced by a1-ARs and AT-Rs that align with their distinct subcellular 
localization and activation of proximal signaling to produce differential activation of 
hypertrophic signaling pathways.  
 
5.2 Introduction 
The current model of Gq-receptor hypertrophic signaling is largely based on ET-
R signaling and suggests that sarcolemmal Gq-receptors produce IP3-dependent 
intranuclear calcium release, activation of calmodulin kinase, phosphorylation and 
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nuclear export of histone deacetylases (HDACs), and de-repression of transcription. This 
model is notable for explaining how cytosolic calcium transients required for contraction 
are segregated from IP3-dependent nuclear calcium signals required for hypertrophic 
signaling. However, it is not entirely clear how this model might reconcile the data 
suggesting Gq-receptors induce unique physiology or our model of nuclear a1-
cardioprotective signaling. Here, we report for the first time that in adult cardiac 
myocytes, a1-ARs and AT-Rs localize to and activate PLCb1 in unique subcellular 
compartments. Further, we demonstrate that these compartmentalized proximal signals 
induce differential activation of nuclear hypertrophic signaling pathways to produce 
unique hypertrophic transcriptomes. Finally, these data provide a potential mechanistic 
explanation for distinct Gq-receptor function in adult cardiac myocytes and suggest a 
revision of the classic model of excitation-transcription coupling. 
 
5.3 Methods  
Mouse Lines 
In this study, male and female C57BL/6J mice (10-15 weeks of age) were used as the 
source of primary adult cardiac myocytes. Male and female C57BL/6J mice were 
included due to no historical evidence indicating differences in receptor (a1-AR and AT-
R) density or signaling cascades. Male FVB/NJ (10-11 weeks of age) mice were used for 
infusion of agonist to measure Gq-receptor induced hypertrophic transcriptional 
responses. Only male FVB/NJ mice were used for the Gq-receptor induced hypertrophic 
transcriptional responses due to historical evidence indicating a more robust 
hypertrophic response by male mice. All FVB/NJ mice were randomized to treatment 
groups (vehicle (n=6), AngII (n=4), or PE (n=4)). For implantation of mini-osmotic pumps, 
mice were anesthetized under isoflurane (3% for induction, 1.5% for maintenance) and 
animals were treated with buprenorphrine (1 mg/kg) for post-surgical analgesia. After 
implantation of osmotic pumps, animals were housed singly for the duration of the study 
to ensure safety of the incision site. All animals were treatment naïve and housed under 
12-hour light/dark cycle and fed standard chow. The use of all animals in this study 
conformed to the PHS Guide for Care and Use of Laboratory Animals and was approved 
by the University of Minnesota Institutional Animal Care and Use Committee. The 
University of Minnesota provides AAALAC-accredited services and resources for using 
	 66	
animals in research, including animal ordering, care, facilities, housing, and training for 
researchers and lab personnel.  
 
Cell Lines 
The cell line used in this study are HEK293 cells used for adenoviral amplification. 
HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were 
incubated at 5% CO2 and 37°C. No information on sex or cell authentication information 
is available for this cell line.  
 
Isolation and Culture of AMVM  
As we have described previously (161), adult mouse ventricular myocytes were isolated 
from wild-type male and female C57BL/6J mice between 10 and 15 weeks of age. 
Briefly, mice were anesthetized with isoflurane (3% for induction, 1.5% for maintenance), 
injected with heparin (100 IU/mL), the pleural cavity was opened and the heart removed, 
cannulated on a retrograde perfusion apparatus, and perfused with collagenase type II 
to dissociate ventricular myocytes. Isolated cardiac myocytes were plated at a density of 
50 rod-shaped myocytes per square millimeter on laminin-coated culture dishes. 
Myocytes were cultured in MEM with Hank’s Balanced Salt Solution, 1 mg/ml bovine 
serum albumin, 10 mM 2,3-butanedione monoxime, and 100 U/ml Penicillin in a 2% CO2 
incubator at 37°C. All reagents were purchased from Sigma Aldrich unless otherwise 
specified. Full details of the buffers, enzymes, cell culture medium, all procedures for 
isolation and culturing of AMVM and a detailed diagram of the perfusion apparatus were 
described in detail previously (161). 
Following plating, myocytes were counted at a magnification of 20X to determine cell 
viability. Adenovirus was added based on previously determined multiplicity of infections. 
Infected myocytes were incubated in a 2% CO2 incubator at 37°C for 40 hours. 
 
Adenoviral Production 
The HDAC5-GFP adenovirus was a gift from Timothy McKinsey, Ph.D. (183).   
Viral amplification and purification: The HDAC5 virus was amplified for three rounds of 
replication. The HDAC5 virus was purified using OptiPrep gradients and 
ultracentrifugation (35,000 x g for 18 hours). The HDAC5 virus was titered using Adeno-
X Rapid Titer Kit per manufacturer’s instructions. For experiments, cultured AMVM were 
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counted at 20X and infected with adenoviruses at the following multiplicity of infection 
500 HDAC5-GFP (titer: 6.1 x 1015).  
 
 
 
Quantification and Statistical Analysis 
 
Analysis of HDAC5 Nuclear Export 
To measure Gq-receptor induced HDAC5 nuclear export, cultured AMVM plated on 
coverslips were infected with 5,000 MOI HDAC5-GFP for 40 hours at 37°C. Myocytes 
were treated with either vehicle, PE (20 µM), or AngII (100 nM) for either 30 minutes or 1 
hour at 37°C. Pretreatment with 2-APB (2 µM) was carried out for 30 minutes at 37°C 
prior to PE treatment. Myocytes were fixed and mounted exactly as described for a1-
QDot 565. Confocal images were captured on an Olympus FluoView FV1000 IX2 
Inverted Confocal Microscope at 60X magnification (oil immersion).  
 
Analysis of Hypertrophic Transcriptional Profiles  
To analyze Gq-receptor hypertrophic transcriptional profiles, 10 to 11 week old FVB/NJ 
mice were dosed at 30 mg/kg/day for PE (n=4), 0.5 mg/kg/day for AngII (n=4), or vehicle 
(n=6) using implanted micro-osmotic pumps for 72 hours. Total RNA was harvested from 
isolated myocytes using RNeasy Fibrous Tissue Mini Kit, following manufacturer’s 
instructions. Using total RNA as input, rRNA was removed via oligo-dT purification to 
enrich for mRNA, followed by random-primed reverse-transcription, second-strand cDNA 
synthesis, ligation of indexed adaptors for Illumina sequencing, and subsequent library 
creation from the resulting double-stranded DNA. 125 base pair paired end stranded 
RNA Sequencing was performed by the University of Minnesota Genomics Core using 
the Illumina HiSeq 2500 resulting in 10-20 million reads per sample.  
 
Statistical Analysis 
All data plotting and statistical analysis was performed using Prism 6 software. All 
information on statistical parameters can be found in figure legends. HDAC5-GFP 
fluorescent intensity was measured for whole myocytes and nuclei using FIJI. Nuclear 
fluorescence was subtracted from whole cell fluorescence to calculate cytosolic 
fluorescence. Ratio of cytosolic to nuclear fluorescence was plotted. Data were analyzed 
by One-Way ANOVA and P<0.05 was considered significant. 
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 For RNAseq analysis, 126bp FastQ paired-end reads (n=11.6 Million per sample) 
were trimmed using Trimmomatic (v 0.33) enabled with the optional “-q” option; 3bp 
sliding-window trimming from 3’ end requiring minimum Q30. Quality control checks on 
raw sequence data for each sample were performed with FastQC. Read mapping was 
performed via Bowtie (v2.2.4.0) using the UCSC mouse genome (mm10) as reference. 
Gene quantification was done via Cuffquant for FPKM values and Feature Counts for 
raw read counts. Differentially expressed genes were identified using the edgeR 
(negative binomial) feature in CLCGWB (Qiagen) using raw read counts. We filtered the 
generated list based on a minimum 1.7X Absolute Fold Change and FDR corrected p < 
0.05. The filtered gene list was then used for further analysis of hypertrophic, survival-
signaling, inotropic, and fibrotic gene ontologies. Search criterion were defined by 
commonly associated terms used in concordance with hypertrophy, survival-signaling, 
inotropy, and fibrosis, respectively. Search terms for hypertrophy were NF-kappa B, 
GATA4, MEF2, NFAT, ANF, TGF, hypertrophy, myosin heavy chain, MHC, c-myc, c-fos, 
cell growth, and natriuretic. Search terms for survival-signaling were ERK, MAPK, 
apoptotic, apoptosis, survival, and cell death. Search terms for inotropy were calcium, 
contraction, sarcoplasmic reticulum, troponin, myosin, actin, ryanodine, protein kinase C, 
and sarcomere. Search terms for fibrosis were collagen, matrix metalloprotease, fibrosis, 
fibroblast, extracellular matrix, matrix. All genes are represented with Entrez gene 
names (https://www.ncbi.nlm.nih.gov/gene). Prcomp was used to perform principal 
component analysis on a file containing normalized FPKM values across 14 samples 
with 24,345 genes across 3 groups. Ggplot was used to draw the PCA graph and 
stat_ellipse was used to delineate the 95% confidence intervals.  
 
Data Availability 
RNA-Seq Data Set is available at http://dx.doi.org/10.17632/pbw8ww4k55.1.   
 
5.4 Results 
a1-ARs, but not AT-Rs, induce IP3-dependent nuclear export of HDAC5 in adult 
cardiac myocytes.  
Gq-receptors induce hypertrophy through a mechanism known as excitation-
transcription coupling (43). Conventionally, sarcolemmal Gq-receptor-mediated 
production of IP3 elicits intranuclear calcium release from the nuclear envelope, 
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activation of calmodulin kinase type II, and phosphorylation and nuclear export of 
HDAC5 (43). Nuclear compartmentalization of IP3-dependent calcium release allows 
myocytes to distinguish calcium required for contraction from calcium required for 
transcriptional signaling. Here, we examined whether differentially localized Gq-
receptors would have the same effect on HDAC5 export. In AMVM expressing HDAC5-
GFP, PE but not AngII induced a moderate, but significant, export of HDAC5 at 30 
minutes (Figure 5.1A top panels, quantified in 5.1B). By 1 hour, PE significantly induced 
HDAC5 nuclear export, whereas AngII did not (Figure 5.1A bottom panels, quantified in 
5.1C), consistent with previous reports for PE  (184). To determine if PE-induced 
HDAC5 nuclear export was IP3-dependent, AMVM expressing HDAC5-GFP were 
pretreated with the IP3R inhibitor 2-aminoethoxydiphenyl borate (2-APB). Pretreatment 
with 2-APB abolished the PE-mediated HDAC5 nuclear export (Figure 5.1D, quantified 
in 5.1E). Taken together, these results indicate that a1-ARs, but not AT-Rs, activate IP3-
dependent HDAC5 nuclear export in AMVM.  
 
a1-ARs and AT-Rs induce unique transcriptomes in adult cardiac myocytes 
Physiologically, a1-ARs and AT-Rs have diametrically opposed effects on the 
heart. a1-ARs induce physiologic hypertrophy, survival signaling, positive inotropy, and 
are not associated with fibrosis (14). AT-Rs induce pathologic hypertrophy, myocyte cell 
death, negative inotropy, and are pro-fibrotic  (185, 186). We hypothesized that these 
differences in the physiologic function of cardiac a1-ARs and AT-Rs would be revealed 
in their transcriptomes and reflective of their distinct subcellular localization. To evaluate 
a1-AR and AT-R transcriptomes, we treated mice with vehicle, PE (30 mg/kg/day), or 
AngII (0.5 mg/kg/day) continually for 3 days using osmotic mini-pumps, at which point, 
we isolated cardiac myocytes and performed RNASeq. Consistent with our HDAC5 
results and that HDAC5 activation relieves transcriptional repression, a1-ARs induced a 
larger transcriptional response, with a total of 806 genes changed (increased or 
decreased) 1.7-fold versus vehicle, whereas AT-Rs induced a much smaller response 
with only 173 genes changed 1.7- fold versus vehicle. 1.7 fold expression over vehicle 
was used as the threshold since adult cardiac myocytes are post-mitotic and generally 
do not induce large transcriptional responses. Interestingly, between a1-ARs and AT-Rs, 
155 genes were changed by both agonists, indicating a1-ARs induced 651 unique 
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genes, whereas AT-Rs induced only 18 unique genes (Figure 5.2A). These results 
suggest that the AT-R transcriptome is largely a subset of the a1-AR transcriptome in 
cardiac myocytes. 
  To parse the RNASeq results further, we initially attempted to utilize the Ingenuity 
Pathway Analysis (IPA) software, but the majority of the database is derived from 
oncogenic studies and lacks cardiac myocyte specific pathways. Thus, we derived our 
own analysis and sorted genes that were regulated by a1-ARs alone, AT-Rs alone, or 
were in common between the two into gene ontologies corresponding to Gq-receptor 
biology: hypertrophy, survival signaling, inotropy, and fibrosis (Figure 5.2B, Tables 5.1-
5.4). a1-ARs most robustly altered genes in all categories as compared to common 
genes and AT-R only genes. While surprising that a1-ARs altered more fibrotic genes 
than AT-Rs, these genes are not classically associated with alterations in the 
extracellular matrix leading to fibrosis (Table 5.4). Finally, principle component analysis 
(PCA) was performed to determine the degree of difference between vehicle, AngII, and 
PE treated samples (Figure 5.2C). Principle component 1 (PC1) accounted for 66% of 
the variance and aligned with the a1-AR transcriptomes, whereas PC2 accounted for 
22% of the variance and aligned with the AT-R transcriptome. The AngII treated samples 
also closely grouped with the vehicle treated samples indicating that AT-Rs do not 
induce a highly distinct transcriptome from control, consistent with our gene ontology 
results (Figure 5.2A and 5.2B) The top 25 genes determining PC1 and PC2 are 
presented in Figure 5.2D. Taken together, a1-ARs robustly activate transcription in adult 
cardiac myocytes whereas AT-Rs minimally activate transcription. These results identify 
distinct differences in the transcriptomes induced by a1-ARs and AT-Rs that align with 
their distinct subcellular localization and activation of proximal signaling to produce 
differential activation of nuclear hypertrophic signaling pathways.  
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Figure 5.1. a1-ARS induce HDAC5 export, whereas AT-Rs do not.  
A. a1-ARs activate HDAC5 nuclear export, whereas AT-Rs do not.  WT AMVM 
expressing HDAC5-GFP were treated with either vehicle (left panels), 20 µM PE (middle 
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panels), or 100 nM AngII (right panels) for either 30 minutes (top panels) or 1 hour 
(bottom panels) at 37°C. Scale bar = 10 µm. B and C. Quantification of HDAC5 export 
induced by a1-ARs and AT-Rs. Cytoplasmic and nuclear GFP fluorescence was 
quantified using FIJI, and the ratio of cytoplasmic to nuclear GFP was plotted as an 
indication of HDAC5 nuclear export at 30 minutes (B) and 1 hour (C). Data are 
represented as mean ± SEM. Data were analyzed by one-way ANOVA, and P<0.05 was 
considered significant. Vehicle (n=12 myocytes from 6 hearts); PE (n=12 myocytes from 
6 hearts); AngII (n=12 myocytes from 6 hearts) D. HDAC5 export is inhibited in the 
presence of IP3R inhibitor, 2-APB. WT AMVM expressing HDAC5-GFP were treated with 
2-APB (2 µM, 30 minutes at 37°C) prior to treatment with PE (1 hour at 37°C, middle 
panel). Scale bar = 10 µm. D. Quantification of HDAC5 export in the presence of IP3R 
inhibitor, 2-APB. The ratio of cytoplasmic to nuclear GFP was calculated and plotted. 
Data are represented as mean ± SEM. Data were analyzed by one-way ANOVA, and 
P<0.05 was considered significant. Vehicle (n=12 myocytes from 6 hearts); 2-APB (n=12 
myocytes from 6 hearts); PE (n=12 myocytes from 6 hearts); PE+2-ABP (n=12 myocytes 
from 6 hearts).  
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Figure 5.2. a1-ARs robustly activate transcriptional responses in adult cardiac 
myocytes whereas AT-ARs do not.  
A. Venn diagram of a1-AR- and AT-R-induced transcriptomes. The gene list generated 
by RNAseq was filtered based on a minimum 1.7X absolute fold change and FDR 
corrected P<0.05. PE treatment altered 801 transcripts (655 unique) by at least 1.7 fold, 
whereas AngII only altered 173 (18 unique), with 155 common between the two 
treatments. B. Gene ontology analysis a1AR- and AT-R-induced transcriptomes. Gq-
receptors regulate hypertrophy, survival signaling, inotropy, and fibrosis. Therefore, 
using non-overlapping search terms unique to these different biologic functions, genes 
were sorted into subclasses of hypertrophy, survival signaling, inotropy, and fibrosis. The 
total number of genes altered (increased and decreased) in common or by PE or AngII 
alone are plotted in the graph. Search terms used to sort genes associated with 
hypertrophy: NF-kappa B, GATA4, MEF2, NFAT, ANF, TGF, hypertrophy, myosin heavy 
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chain, MHC, c-myc, c-fos, cell growth, natriuretic; Search terms for survival signaling: 
ERK, MAPK, apoptotic, apoptosis, survival, cell death; Search terms for inotropy: 
calcium, contraction, sarcoplasmic reticulum, troponin, myosin, actin, ryanodine, protein 
kinase C, and sarcomere; Search terms for fibrosis: collagen, matrix metalloprotease, 
fibrosis, fibroblast, extracellular matrix, matrix. C. Principle Component Analysis of a1-
AR and AT-R induced transcriptomes. Principle component analysis of fragments per 
kilobase of exon per million reads mapped (FPKM). PC1 determined 66% of all variance 
between samples. PC2 determined 22% of all variance between samples. D. Top 25 
genes determining PC1 and PC2. Top 25 genes for PC1 and PC2 were determined 
using FPKM loadings.  
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Table 5.1. Molecular function of Hypertrophic Genes induced by a1ARs, ATRs, or 
in common.  
As described in Figure 5.2, genes were sorted into Gq-receptor functional subclasses of 
hypertrophy, survival signaling, inotropy, and fibrosis using non-overlapping search 
terms unique to Gq-receptor biologic functions. Search terms for hypertrophy were:	NF-
kappa B, GATA4, MEF2, NFAT, ANF, TGF, hypertrophy, myosin heavy chain, MHC, c-
myc, c-fos, cell growth, natriuretic. Hypertrophic genes were further sorted by molecular 
Supplementary Table 1. Hypertrophy Phenotype Genes 
Gene Ontology 
Category 
AngII PE Common 
Immune Response 0 19 5 
Increase 0 19 5 
 - Cd14, Cd44, Cd84, Clec4n, 
Fcer1g, Fcgr1, Fcgr3, H2-
DMb1, H2-DMb2, Havcr2, 
Il1b, Ncf4,Slc11a1, Tgfb3, 
Tlr1, Tnfrsf11a, Tnfsf11, 
Tnfsf14, Trem2 
Fcgr2b, Il6, Inhba, 
Lgals3, Tgfb2 
Decrease 0 0 0 
 - - - 
Kinase & Phosphatase 
Activity 
0 6 4 
Increase 0 6 3 
 - Btk, Ikbke, Pak1, Pi16, 
Pik3ap1, Rcan1 
Cdkn1a, Nckap1l, 
Ptk2b 
Decrease 0 0 1 
 - - Akap5 
Transcription Regulation 0 7 1 
Increase 0 6 1 
 - Bcl3, Col14a1, Igfbp2, Il7r, 
Nupr1, Zc3h12d 
Spi1 
Decrease 0 1 0 
 - Nlrc5 - 
G-protein Coupled 
Receptors & Activity 
0 6 0 
Increase 0 5 0 
 - Frzb, Htr2b, Rasgrp4, Rrad, 
Sfrp1 
- 
Decrease 0 1 0 
 - Adra1a - 
Growth Factor 0 4 2 
Increase 0 4 2 
 - Cgref1, Ctgf, Hbegf, Igf1 Csf2rb, Fhl1 
Decrease 0 0 0 
 - - - 
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function and listed in the table, with the number of genes increased or decreased 
indicated along with the specific genes in each category. 
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Table 5.2. Molecular function of Survival Signaling Genes induced by a1ARs,  
ATRs, or in common.  
As described in Figure 5.2, genes were sorted into Gq-receptor functional subclasses of 
hypertrophy, survival signaling, inotropy, and fibrosis using non-overlapping search 
terms unique to Gq-receptor biologic functions. Search terms for survival signaling were: 
ERK, MAPK, apoptotic, apoptosis, survival, cell death. Survival signaling genes were 
further sorted by molecular function and listed in the table, with the number of genes 
increased or decreased indicated along with the specific genes in each category. 
Supplementary Table 2. Survival Signaling Phenotype Genes 
Gene Ontology 
Category 
AngII 
Only 
PE Only Common 
Immune Response 0 18 12 
Increase 0 18 12 
 - Ccl12, Ccl4, Ccl6, Ccr1, 
Cd44, Cd84, Gdf15, Gdf6, 
Il1b, Il33, Lgals1, Lif, Tgfb3, 
Tnfrsf11a, Tnfrsf11b, 
Tnfrsf23, Tnfsf11, Tnfsf14 
Ccl2, Ccl9, Ccl22, 
Ccr2, Cd24a, Crlf1, 
Il6, Il11, Il1rn, 
Inhba, Socs3, 
Tgfb2 
Decrease 0 0 0 
 - - - 
Kinase & Phosphatase 
Activity 
0 20 7 
Increase 0 15 6 
 - Dram1, Dusp26, Havcr2, Hck, 
Hk3, Ikbke, Pak1, Pak3, 
Pak6, Peg10, Pik3ap1, Ptn, 
Ptpn6Ptprc, Sphk1 
Cdkn1a, Hsb1, 
Mylk2, Nckap1l, 
Ptk2b,  Snai1 
Decrease 0 5 1 
 - Dusp4, Ephb1, Map4k2, Ptprr, 
Prkcg 
Kit 
G-protein Coupled 
Receptors & Activity 
0 16 0 
Increase 0 14 0 
 - Ccl7, Ccl8, Ccr5, Cdh1, 
Cx3cr1, Frzb, Gpnmb, Htr2b, 
Lpar3, Mpz, Ncf2, Ntsr2, 
Rgs14, Sfrp1 
- 
Decrease 0 2 0 
 - Adra1a, Brinp1 - 
Transcription Regulation 2 6 4 
Increase 1 5 3 
 Atf3 Creb3l1,  Irf5, Isl1, Myc, 
Twist1 
Ankrd2, Plac8, 
Spi1 
Decrease 1 1 1 
 Sox4 Sox7 Mycn 
Enzyme 0 11 0 
Increase 0 10 0 
	 78	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3. Molecular function of Inotropy Genes induced by a1ARs, AT-Rs, or in  
common.  
Search terms for inotropy were: calcium, contraction, sarcoplasmic reticulum, troponin, 
myosin, actin, ryanodine, protein kinase C, and sarcomere. Inotropy genes were further 
Supplementary Table 3. Inotropy Phenotype Genes 
Gene 
Ontology 
Category 
AngII PE Common 
Kinase & 
Phosphatase 
Activity 
0 23 7 
Increase 0 20 5 
 - Bmp1, Camk2n2, Ccl4, Ccr1, 
Cnn1, Coro1a, Dbn1, Dpysl3, 
Fbn1, Fkbp10, Hck, Myo1g, 
Pacsin1, Pak1, Pak3, Pak6, Plek, 
Ptpn6, Ptprc, Sphk1 
Acp5, Fgr, Mylk2, 
Nckap1l, Ptk2b 
Decrease 0 3 2 
 - Dgkh, Mylk4, Prkcg Akap5, Kit 
G-protein 
Coupled 
Receptors & 
Activity 
0 19 3 
Increase 0 15 2 
 - Ackr1, Adgre1, Cdh1, Dock2, 
Fpr2, Fstl1Htr2b, Lpar3, Rab27b, 
Rac2, Rhou, Sfrp1, Tgm2, 
Tnfsf11, Was 
Lrp8, Ptafr 
Decrease 0 4 1 
 - Adra1a, Celsr3, Gpr17, Tbxa2r Apln 
Immune 
Response 
0 12 6 
Increase 0 12 6 
 - Alox5ap, C3ar1, C5ar1, Ccl12, 
Ccr5, Cd84,Cxcl13, Gpr35, Il1b, 
Ncf1, Panx1, Runx1 
Ccl2, Cd24a, Crlf1, 
Sele, Selp, Tgfb2 
Decrease 0 0 0 
 - - - 
Ion Channel 0 13 4 
Increase 0 9 4 
 - Atp1a3, Clca3a, Fzd2, Itih4, 
Kcnab2, Kcnn4, Slc8a2, Trem2, 
Trpm2 
Hcn1, Ltbp2, Sypl2, 
Syt12 
Decrease 0 4 0 
 - Ano10, Cacna1s, Clcn1, Cracr2a - 
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sorted by molecular function and listed in the table, with the number of genes increased 
or decreased indicated along with the specific genes in each category. 
 
Table 5.4. Molecular function of Fibrosis Genes induced by a1ARs, AT-Rs, or in 
common.  
As described in Figure 5.2, genes were sorted into Gq-receptor functional subclasses of 
hypertrophy, survival signaling, inotropy, and fibrosis using non-overlapping search 
terms unique to Gq-receptor biologic functions. Search terms for fibrosis were: collagen, 
Supplementary Table 4. Fibrosis Phenotype Genes 
Gene Ontology Category AngII PE Common 
Extracellular Matrix 
Modulation 
1 27 11 
Increase 1 27 11 
 Mmp9 Acan, Adamts2, Col11a1, 
Col12a1, Col14a1, 
Col16a1, Col18a1, 
Col6a1, Col6a2, Eln, 
Emilin1, Fbln2, Fbn1, 
Fbn2, Frem1, Itga11, 
Itgb3, Mmp12, Mmp14, 
Mmp19, Mmp8, Mrc2, 
P4ha3, Pcolce, Postn, 
Serpinh1, Vacn 
Adam8, 
Adamts4, 
Col1a1, 
Col1a2, 
Col3a1, 
Col5a1, 
Col5a2, Mmp3, 
Spp1, Thbs1, 
Thbs4 
Decrease 0 0 0 
 - - - 
Immune Response 0 6 7 
Increase 0 6 7 
 - Bgn, Ccdc80, Cd44, 
Tgfb3, Tnfsf11b 
Ccl2, Cxcl5, 
Il17ra, Il6, 
Itgb2, Lgals3, 
Tgfb2 
Decrease 0 0 0 
 - - - 
Kinase & Phosphatase 
Activity 
0 7 2 
Increase 0 6 2 
 - Ccnb1, Cnn1, Dusp26, 
Fam20c, Pak1, Pak3 
Cdkn1a, Ptk2b 
Decrease 0 1 0 
 - Ptprz1 - 
Transcription Regulation 0 7 0 
Increase 0 5 0 
 - Bcl3, Creb3l1, Myc, Nupr1, 
Sh3pxd2b 
- 
Decrease 0 2 0 
 - Dach1, Tcf15 - 
Peptidase 0 4 3 
Increase 0 4 3 
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matrix metalloprotease, fibrosis, fibroblast, extracellular matrix, matrix. Fibrosis genes 
were further sorted by molecular function and listed in the table, with the number of 
genes increased or decreased indicated along with the specific genes in each category. 
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5.5 Discussion  
Here we report our findings that a1-ARs and AT-Rs differentially activate 
transcriptional machinery and transcriptional responses in adult cardiac myocytes. Gq-
receptors differentially activate transcriptional machinery, with a1-ARs, but not AT-Rs, 
promoting IP3 sensitive HDAC5 export. We also found that Gq-receptors differentially 
activate transcriptional responses with a1-ARs inducing robust transcriptional responses 
in genes that correspond to a1-AR physiologic function, whereas AT-Rs activate genes 
that are largely a subset of a1-AR regulated genes. These results are the first indicating 
that a1-ARs and AT-Rs differentially regulate transcription in adult cardiac myocytes and 
support the idea that this is due to their localization and compartmentalization of 
proximal signaling cascades.  
 The first report of IP3 sensitive transcriptional regulation in adult cardiac myocytes 
was based on ET-Rs (43). In that report, sarcolemmal ET-Rs activate sarcolemmal 
PLCb1 to produce IP3 which traverses the cardiac myocyte and activates IP3Rs in the 
inner nuclear membrane to induce HDAC5 export (43). Our results indicate a more 
nuanced view of this signaling cascade with nuclear a1-ARs inducing IP3 sensitive 
HDAC5 export, but sarcolemmal AT-Rs failing to induce HDAC5 export. This seemingly 
conflicting result can be explained by the localization of these receptors in adult cardiac 
myocytes: a1-ARs at the nuclear membrane, AT-Rs at the sarcolemma, and ET-Rs at 
the bottom of the t-tubules which are in close proximity to the nuclear membrane (187). 
Our results indicate that IP3 must be produced in close apposition to the nuclear 
membrane in order to induce transcriptional activation indicating that a1-ARs and ET-Rs, 
but not AT-Rs, are capable of inducing this signaling cascade.  
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
  
	 83	
6.1 Conclusions 
Here, we identified a potential mechanistic explanation for unique Gq-receptor 
function in adult cardiac myocytes predicated upon subcellular compartmentalization of 
proximal Gq-receptor signaling. We found that a1-ARs localize to the nucleus and 
induce intranuclear activation of PLCb1, activate perinuclear and cytosolic ERK, 
stimulate IP3-dependent nuclear export of HDAC5, and activate a robust and unique 
transcriptome associated with hypertrophic, survival, inotropic, and (anti)-fibrotic gene 
programs. Conversely, we observed that AT-Rs primarily localize to, activate PLCb1 at 
the sarcolemma, activate ERK only in the cytoplasm, but have little effect on nuclear 
export of HDAC5, and induce a small transcriptome that is a subset of the a1-
transcriptome. More importantly, these findings are consistent with our hypothesis that 
Gq-receptor localization dictates function by showing compartmentalization of proximal 
Gq-signaling events is correlated with phenotypic outcome in adult cardiac myocytes.  
The excitation-transcription model of Gq-receptor mediated hypertrophic 
signaling in adult cardiac myocytes proposes that sarcolemmal Gq-receptors induce IP3 
production and IP3-sensitive intranuclear calcium release from perinuclear calcium 
stores to activate calmodulin kinase, phosphorylate and induce nuclear export of 
HDAC5, and thereby activate transcription (Figure 6.1A). Both ET-Rs and insulin-like 
growth factor receptors conform to this model (43, 171, 188). Our data indicate that a1-
ARs support this model as well, but interestingly, AT-Rs do not. Although we observed 
AT-R mediated activation of PLCb1 and further downstream activation of ERK, we failed 
to detect AT-R mediated nuclear export of HDAC5, and found a much smaller 
transcriptional response. One interpretation of this result is that close proximity to the 
nucleus is required for Gq-receptor mediated activation of IP3-dependent hypertrophic 
signaling. In support of this interpretation, a1-ARs localize to the inner nuclear 
membrane (154), and ET-Rs and insulin-like growth factor receptors localize to the 
bottom of t-tubules in close apposition to the nucleus in adult cardiac myocytes (187, 
188). Further, the failure of AT-Rs to induce nuclear export of HDAC5 suggest that AT-
R-mediated activation of PLCb1 at the sarcolemma either fails to generate enough IP3 to 
reach the nucleus or that IP3 is degraded before it reaches the nucleus. The potential 
degradation of IP3 prior to reaching the nucleus might be analogous to the 
compartmentalization of cAMP signaling in cardiac myocytes (189). While the current 
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model of excitation-transcription coupling suggests that Gq-receptors induce IP3 
production at the sarcolemma leading to activation of IP3-dependent calcium release at 
the nucleus to induce HDAC5-export and promote gene transcription, our new model is 
more nuanced. Our model suggests Gq-receptor induced IP3 production is 
compartmentalized and that IP3 produced inside the nucleus (or possibly in close 
proximity to the nucleus) induces HDAC5 export to promote gene transcription, whereas 
IP3 produced at a distance from the nucleus (at the sarcolemma) has a different, and 
smaller effect on transcriptional regulation (Figure 6.1B). This would suggest that Gq-
receptor compartmentalization has a large influence on the transcriptomes induced by 
differentially localized Gq-receptors, illustrating the fundamental physiologic importance 
of Gq-receptor compartmentalization.  
The consensus view of cardiac Gq-receptor function has been that Gq-receptors 
mediate pathologic remodeling, promoting maladaptive hypertrophy, myocyte cell death, 
and negative inotropic responses (155). However, in clinical trials of hypertension 
(Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT) 
and HF (Vasodilator Heart Failure Trial, V-HeFT), a1-AR antagonists worsened 
outcomes (190, 191). Further, our studies indicate that a1-ARs are cardioprotective, 
promoting adaptive or physiologic hypertrophy, prevention of cell death, and positive 
inotropic effects identifying a mechanistic basis for the negative results of a1-AR 
antagonists in clinical trials (14). In short, the cardioprotective nature of a1-ARs stands in 
stark contrast to the consensus view of maladaptive Gq-receptor function. Here, our data 
suggests that compartmentalization of Gq-receptors could explain differences in Gq-
receptor function. We demonstrated that although both a1-ARs and AT-Rs activate 
PLCb1, they do so in different subcellular compartments which has a profound effect on 
activation of intranuclear hypertrophic signaling and transcriptional activation. Therefore, 
we suggest that nuclear Gq-receptor signaling, typified bya1-ARs, is cardioprotective. 
Aside from a1-ARs, a small population of functional ET-Rs and AT-Rs localize to the 
nucleus as well (69, 71), although their physiologic significance is unclear. Conversely, 
we observed AT-Rs primarily at the sarcolemma, but not in close proximity to the 
nucleus, which might suggest that Gq-receptor signaling at the sarcolemma is 
pathologic, which is supported by studies with AT-Rs (185, 186). In support of this 
concept, adenoviral mediated expression of the PLCb1b at the sarcolemma induces 
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contractile dysfunction (27). In summary, our hypothetical model of compartmentalized 
Gq-receptor signaling, where nuclear Gq-receptor signaling is cardioprotective, suggests 
a more nuanced view of Gq-receptor function in cardiac myocytes. 
The concept of GPCR compartmentalization in cardiac myocytes is not without 
precedence. In co-cultures of sympathetic ganglionic neurons and neonatal rat cardiac 
myocytes, b1-ARs localize to regions of axonal contact rich in SAP97, AKAP97, 
catenins, and cadherins, whereas b2-ARs are excluded from these domains (164). In 
adult cardiac myocytes, b1-ARs are distributed over the entire sarcolemma, whereas b2-
ARs are restricted deep within T-tubules (165). Finally, platelet-derived growth factor 
receptors, which also signal through Gs, localize to caveolae in cardiac myocytes and do 
not induce an inotropic response (166). These examples demonstrate that cardiac 
myocytes compartmentalize Gs-mediated GPCR signaling, analogous to our findings 
with Gq-receptors. 
Aside from the potential of targeting a1-ARs in HF  (14) our identification of 
cardioprotective nuclear a1-AR signaling also has implications outside of heart. In the 
peripheral vasculature, a1-ARs mediate contraction of smooth muscle, and a1-AR 
antagonists were one of the first treatments for hypertension (HTN). For the same 
reason, a1-AR antagonists are used to treat lower urinary tract symptoms (LUTS) and 
benign prostatic hyperplasia (BPH) (192). Estimates suggest that 9.5 million men over 
65 will develop BPH (193), and of these, 87% will have concomitant HTN and 40% will 
have a previous admission for HF (194). However, a1-AR antagonists increased 
mortality and increased the risk of HF in ALLHAT  (190), and are no longer a first-line 
treatment for HTN, but a1-AR antagonists still used in BPH. Interestingly, nuclear 
localization of a1-ARs in cardiac myocytes does not extend to smooth muscle cells, 
where a1-ARs localize to the cell surface with some fraction internal but not at the 
nucleus (195). Development of a next-generation membrane impermeable a1-blocker 
could reduce cardiotoxic side effects of current a1-blockers, restoring their use in HTN 
and improving their safety in BPH. Therefore, compartmentalization of GPCRs can have 
an important biological impact in multiple systems. 
In conclusion, our findings support a model of compartmentalized Gq-receptor 
signaling in adult cardiac myocytes. This model, largely based on our identification of 
cardioprotective nuclear a1-AR signaling, provides a plausible mechanistic basis to 
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explain the unique function of cardiac Gq-receptors. Additionally, this model suggests a 
re-examination of the classic paradigm of maladaptive Gq signaling in cardiac myocytes 
in favor of a more nuanced view of compartmentalized Gq-receptor signaling. 
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Figure 6.1. Novel model of excitation-transcription coupling in adult cardiac 
myocytes.  
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A. Conventional model of excitation-transcription coupling in adult cardiac myocytes. All 
Gaq-receptors localize to the sarcolemma in adult cardiac myocytes. Upon ligand 
binding, sarcolemmal PLCb1 is activated and cleaves PIP2 into DAG and IP3. DAG goes 
on to activate protein kinase C isoforms (PKCs) and induce contraction. IP3 traverses the 
myocyte and binds to the IP3R on the inner nuclear membrane inducing intranuclear 
calcium release. Calcium activates calmodulin (CaM) and calcium-calmodulin dependent 
protein kinase II (CaMKII), which phosphorylates HDAC5. HDAC5 phosphorylation 
triggers HDAC5 nuclear export and de-repression of transcription. B. Updated model of 
excitation-transcription coupling in adult cardiac myocytes. a1-ARs (nuclear) and AT-Rs 
(sarcolemmal) are differentially localized in adult cardiac myocytes (Figure 2.1). Upon 
ligand binding to either a1-ARs or AT-Rs, PLCb1 is activated either at the nucleus 
(a1AR, Figure 3.4) or at the sarcolemma (AT-R, Figures 3.3). AT-R induced PLCb1 
activation at the sarcolemma fails to induce HDAC5 nuclear export, whereas a1AR 
induced PLCb1 activation at the nucleus induces HDAC5 nuclear export. Furthermore, 
a1-AR induced HDAC5 nuclear export is IP3-dependent (blocked by 2-APB) (Figure 
5.1). Consistent with a1-induced, IP3-dependent HDAC5 nuclear export, a1-ARs induce 
a robust transcriptional response, whereas AT-Rs, which fail to induce HDAC5 export, 
produce a transcriptional response that is largely a subset of a1-AR induced 
transcriptional responses (potentially suggesting a different non-HDAC dependent 
mechanism of transcription) (Figure 5.2).  
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6.2 Future Directions 
Receptor Localization Dictates Function 
The work presented in this thesis concludes that Gq-receptor localization plays a 
central role in Gq-receptor function with sarcolemmal Gq-receptors (AT-Rs) being 
pathologic and nuclear Gq-receptors (a1-ARs) being cardioprotective. Yet, whether 
nuclear localization of Gq-receptors is required for cardioprotective signaling has not 
been tested. We hypothesize that adult cardiac myocyte nuclear Gq-receptors are 
cardioprotective. To test this hypothesis we propose two different strategies: 1) nuclear 
localization of AT-Rs and 2) nuclear localized DREADD-Gq.  
 To test the hypothesis that subcellular localization defines Gq-receptor function 
and that nuclear localization Gq-receptors is cardioprotective, we would drive localization 
of AT-Rs to the nuclear membrane. To accomplish this, we would create a construct with 
the AT1R as a backbone and add a 2x-NLS sequence in order to drive nuclear 
localization, a strategy that we have previously validated. We would focus on the AT1R 
due to previous work indicating that AT1Rs are the main driver of pathologic remodeling 
in the heart (196). We would create an adenoviral construct of the nuclear AT1R, 
express it in AT1R knockout adult cardiac myocytes, activate the receptor using an 
intracellularly applied AT-R ligand, and study PLCb1 activation, ERK activation, and 
hypertrophic transcriptional induction. If our hypothesis is supported, we would expect to 
see that the nuclear AT1R construct would induce nuclear PLCb1 activation, perinuclear 
and cytosolic ERK activation, and induce an HDAC-dependent hypertrophic 
transcriptome more closely resembling that of a1-ARs. If the hypothesis is not supported 
and nuclear expression of AT1Rs does not alter their phenotype, then we could 
conclude that the nuclear localization of Gq-receptors is not sufficient to induce a 
cardioprotective phenotype in adult cardiac myocytes.  
 The second strategy to address the hypothesis that nuclear localization of Gq-
receptors is cardioprotective is to separate receptor specific effects from the G-protein 
effects. Experimentally, we would express a nuclear construct of just the Gaq protein 
called DREADD-Gq in adult cardiac myocytes. DREADDs are designer receptors 
exclusively activated by designer drugs, whereby the DREADD-Gq receptor is only 
activated by clozapine-N-oxide (CNO). We would activate the nuclear DREADD-Gq 
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using CNO and study PLCb1 activation, ERK activation, and hypertrophic transcriptional 
induction. If our hypothesis is supported, we would expect to see that the nuclear 
DREADD-Gq construct would induce nuclear PLCb1 activation, perinuclear and 
cytosolic ERK activation, and induce a hypertrophic transcriptome similar to what we see 
with a1-ARs. If the hypothesis is not supported and nuclear expression of DREADD-Gq 
does not recapitulate the a1-AR phenotype, then we could conclude that the receptor 
and not the G-protein is necessary and sufficient to induce a cardioprotective phenotype 
in adult cardiac myocytes.  
 
Transcriptomics 
The current work presented in this thesis included an RNA-Sequencing study that looked 
at the cardiac myocyte specific effects of either a1-AR or AT-R activation on the 
hypertrophic transcriptome. This study allowed us to look at the total population of 
cardiac myocytes and how activation of either the a1-AR or AT-R affected the 
transcriptional outcome. While useful, recent work in the lab of Dr. Paul Simpson 
indicated that not all adult cardiac myocytes express the a1A-AR, with only about 60% of 
myocytes expressing the receptor. This result was further supported by our work with 
EKAR where we saw ERK activation downstream of a1-ARs in about two-thirds of the 
myocytes. Thus, future work to understand receptor expression in individual cardiac 
myocytes may begin to explain the physiologic responses we see including ERK 
activation and transcriptional responses. In order to begin to uncover these potential 
differences in cardiac myocyte expression of AT-Rs, we would undertake single cell 
transcriptomics. We would isolate adult cardiac myocytes and sort them using flow 
cytometry into single cell suspensions, we would then isolate the RNA on a single cell 
basis, and perform transcriptomics. We expect to see similar results as the a1-AR study 
with not all cardiac myocytes expressing AT-Rs or not all cardiac myocytes expressing 
AT-Rs in similar amounts. This result would allow us to then correlate AT-R expression 
with ERK activation and transcriptional activation and further our understanding of how 
receptor expression effects signal transduction in adult cardiac myocytes.   
 
ET-Rs: The other Gq-Receptor 
The work presented in this thesis focused solely on two prototypical Gq-receptors: AT-
Rs and a1-ARs. Yet in adult cardiac myocytes, there is another Gq-receptor that is 
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expressed: the endothelin receptor (ET-R). While AT-Rs and a1-ARs have seemingly 
opposed effects in adult cardiac myocytes with AT-Rs being pathologic and a1-ARs 
being cardioprotective, ET-Rs fall somewhere in the middle. Previous work with ET-Rs 
using radioligand-binding on fractionated adult cardiac myocytes indicates that ETR 
levels are half that of a1-ARs, and identifies 95% of endogenous ETRs at the plasma 
membrane, with 5% of endogenous ETRs in the nuclear fraction (71, 81{Boivin, 2003 
#2613). Further work using a fluorescent endothelin (ET), the ligand for ET-Rs, localized 
ET-Rs to the bottom of the t-tubules in adult cardiac myocytes, and blocking ET access 
to t-tubules prevented ET-R signaling (187). These lines of evidence indicate that ET-Rs 
do not localize to the surface of the sarcolemma like AT-Rs, and that ET-Rs also do not 
primarily localize to the nuclear membrane like a1-ARs but localize in a separate 
compartment in adult cardiac myocytes. ET-R effects on the adult cardiac myocyte are 
mixed, in cultured cardiac myocytes, ETRs promote survival and positive inotropy (85). 
In mice, ET overexpression induces HF (197), but ETR KO mice show less consistent 
results, with global KO inducing embryonic lethality (148-150), and cardiac-specific KO 
suggesting direct and indirect effects to induce HF (198).  In humans, ETR antagonists 
show no benefit in acute or chronic HF (199). Thus, further work needs to be completed 
to understand how ET-Rs compartmentalized signaling in adult cardiac myocytes.  
 In context of the signaling paradigm presented in this thesis, we hypothesize that 
ET-Rs will share some aspects of AT-Rs (localization, PLCb1 activation) and will also 
share some aspects of a1-ARs (ERK activation, hypertrophic transcriptome). To address 
this hypothesis, we will activate endogenous ET-Rs in adult cardiac myocytes with ET 
and study their localized activation of PLCb1, ERK, and hypertrophic transcriptome. If 
our hypothesis is supported, we would expect to see that endogenous ET-Rs would 
induce sarcolemmal and nuclear PLCb1 activation due to their close proximity to the 
nuclear membrane, perinuclear and cytosolic ERK activation, and induce a hypertrophic 
transcriptome that overlaps both AT-Rs and a1-ARs. This experiment will allow us to 
further define the compartmentalization of Gq-signaling in adult cardiac myocytes.  
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